

CAROL A. KAUFFMAN, M.D

CURRICULUM VITAE

PERSONAL DATA

Carol Ann Kauffman, M.D.

Infectious Diseases Section
Veterans Affairs Healthcare System
2215 Fuller Road
Ann Arbor, Michigan 48105

(734) 761-7984
(734) 769-7039 fax
ckauff@umich.edu

EDUCATION

The Pennsylvania State University, Pre-Medical, B.S., with Distinction,
September, 1961 - March, 1965

The University of Michigan Medical School, M.D. with Distinction,
September, 1965 - June, 1969

POSTDOCTORAL TRAINING

Internship: Internal Medicine, University of Michigan Medical Center,
July, 1969 – June, 1970

Residency: Internal Medicine, University of Michigan Medical Center,
July, 1970 – June, 1971

Fellowship: Infectious Diseases, University of Cincinnati Medical Center,
July, 1971 – June, 1973

ACADEMIC APPOINTMENTS

Assistant Professor of Internal Medicine, University of Cincinnati Medical School,
July, 1973 - June, 1977

Research Associate, Cincinnati Veterans Affairs Medical Center, July, 1974- February, 1976

Assistant Professor of Internal Medicine, University of Michigan Medical School,
July, 1977 - June, 1978

Associate Professor of Internal Medicine, University of Michigan Medical School,
July, 1978 - June, 1981

Professor of Internal Medicine, University of Michigan Medical School, July, 1981 - Present

ACADEMIC ADMINISTRATIVE APPOINTMENTS

Chief, Infectious Diseases Section, Cincinnati Veterans Affairs Medical Center,
February, 1976 - June, 1977

Chief, Infectious Diseases Section, Ann Arbor Veterans Affairs Medical Center,
July, 1977- Present

Assistant Chief, Medical Service, Ann Arbor Veterans Affairs Medical Center,
September, 1978 - October, 1983

Assistant Dean for Student Affairs, University of Michigan Medical School,
January, 1986 - December, 1991.

ADVISORY PANELS, TASK FORCES, CONSULTANCIES

Task Force on Methicillin-resistant *Staphylococcus aureus*, American Hospital Association,
1991-1993

Scientific Advisor, Geriatric Oral Science Project, University of Michigan, 1992-2000.

Mycoses Study Group Liaison-Systemic Mycoses Pathogens Study Group, AIDS Clinical
Trials Group, NIH, 1993-1997

Advisory Panel, Zeneca Pharmaceuticals, 1993-1994

Pharmacy Fungal Program, University of Rhode Island, 1993- 1996

Immunology and Aging: Vaccine Development for Immunization of the Elderly. NIAID and
NIA, 1994

Mycology Consultants Forum, Healthways Communications/Janssen Pharmaceutica, 1994

Advisory Panel, Pfizer-Roerig, Inc. Azole resistance, 1994-1995

Advisory Board, International Guidelines for the Management of Invasive Candidiasis, 1995

Expert Advisory Panel on Infectious Disease Therapy, United States Pharmacopeia,
1995-2005

Sandoz International Advisory Board, 1996

—————, Nasal Advisory Board, 1995-1997

Advisory Board, Council on Opportunistic Infections 1996-1997

TAP Pharmaceuticals, Consultant for ——— development, 1997-1998

Aronex Pharmaceuticals, Consultant for ————— trials, 1997-1998

IntraBiotics, Consultant for new drug development, 1997-2001

Advisory Panel, Current Drugs, Ltd., 1998-2002

Chairperson, Data safety monitoring board, —————
—————, Schering-Plough Research Institute, 1999-2003

VRE Steering Committee, —————
————— IntraBiotics, 2000-2001; ————— 2001-present

Pfizer ——— Mock FDA Advisory Board, 2001

External Peer Review Committee, CDC Mycotic Diseases Branch, November 2002

Advisory Panel, ————— 2002-present

Advisory Panel on Nosocomial Infections, ————— 2002-present.

Advisory Council, _____, Respiratory Infections in Older Adults, 2002-present.

Advisory Council, _____, 2004-present.

OTHER ACTIVITIES

Honorary, Galens Medical Society, 1980- 1983; 1985- 1989; 1992 - 1994 Prefect - 1981

Advisor, Alpha Omega Alpha, Michigan Chapter, 1981 - 1989

Advisor, STATS (Student Teaching AIDS to Students) Program, 1991 - 1994

Advisor, AMWA, University of Michigan Chapter, 1992 - 1994

Mentor for Summer Student Minority Research Program, University of Michigan Medical School, 1996 - 2001

SCIENTIFIC ACTIVITIES

Member, VA Midwest Regional Research Advisory Group, 1978 – 1981

Chairperson, VA Midwest Regional Research Advisory Group, 1980 - 1981

Member, VA Research Advisory Committee, 1981 - 1986

Program Specialist in Infectious Diseases, Veterans Affairs, 1984 - 1987

Task Force on Immunology and Aging, NIAID and NIA, 1994

Special NIAID Review Committee "Basic Biology of Immune Responses for Vaccine Research", 1994

NIAID Special Emphasis Panel, RFA-AI-98-013, Adult Therapeutic Clinical Trials Program for AIDS, 1999

Member, NIH/NIAID Mycoses Study Group, 1979 - 2000

Principal Investigator, Subproject on Endemic Mycoses, Mycoses Study Group, 1990 - 2000

Steering Committee, Bacterial and Mycotic Study Group, 2000 – 2005

Steering Committee, Trans-Net Surveillance of Invasive Fungal Infections among Organ Transplant Recipients, 2003 – present.

Masked Data Review Committee, Randomized double-masked trial of caspofungin versus placebo on prophylaxis of invasive candidiasis in high-risk adults in the critical care setting, 2004 – present.

Editorial Boards and Editorships

Editorial Board, Clinical Infectious Diseases, 1995-present

Editorial Board, Mycoses, 1996-2004; Deputy Editor, 2004-present

Editorial Board, Antibiotics for the Clinician, 1996-2002

Kauffman CA (editor): The changing face of infectious diseases. Patient Care. 1997

Bula C and Kauffman CA (editors): Infections in the elderly. Bailliere's Clinical Infectious Diseases, 1998

Editorial Board, Medscape, Infectious Diseases, 1999-2001

Advisory Board, Infectious Diseases and Therapy Series, Marcel Dekker, Inc., 2000-present

Editorial Board, Journal American Geriatrics Society, 2000-present

Section Editor, Fungal Infections, Current Treatment Options in Infectious Diseases, 2000-2001.

Editor, Mycology Initiative Monograph Series, 2000-present

MKSAP Contributing Committee Member, Fungal Diseases, 2002-present

Guest Editor, Seminars in Respiratory and Critical Care Medicine, Pulmonary Fungal Infections, 2004

Editorial Board, Life Sciences Business Technology Review, 2004-present

Editorial Board, Infectious Diseases in Clinical Practice, 2005-present

GRANT SUPPORT

Recent

Clinical trials of antifungal therapies. NIAID/NIH Mycoses Study Group, 1995 - 2000. Principal Investigator, Endemic Mycoses Subproject. William Dismukes, M.D., Principal Investigator for MSG Contract.

Mupirocin prophylaxis for staphylococcal infection in nursing homes. NIA Claude Pepper Center Grant, 1997-2001, Co-Investigator. Suzanne F. Bradley, M.D., Principal Investigator.

_____, 2000-2001. Co-Principal Investigator with Dr. _____

A randomized, double-blind trial comparing AmBisome and fluconazole in high risk liver transplant patients. NIAID/MSG/Fujisawa, 2000-2001. Principal Investigator.

Epidemiology of candidemia at the University of Michigan Medical Center over the last decade. 1999-2002. Principal Investigator.

Effect of introduction of an _____, 2000-2002. Co-Investigator, _____, Principal Investigator.

Epidemiology of vancomycin-resistant enterococci in liver transplant recipients. 1999-2003. Co-Principal Investigator with _____

_____, 2001-2003. Principal Investigator.

Validation of predictive factors for Candidiasis in ICU patients. Mycoses Study Group and Merck, Inc., 2002-2003. Principal Investigator.

_____ , Principal Investigator.
_____ , Principal Investigator.
_____ , Principal Investigator.
2002-2003. Co-Investigator. _____ , Principal Investigator.

Adverse events and patient outcomes associated with community-based _____
therapy. _____ 2002-present. Co-investigator. _____ , Principal
Investigator.

Retrospective study of incidence of VRE BSI in patients with oncologic or hematologic
disorders. _____ 2002-present. Principal Investigator.

A phase II, randomized, open label, multicenter trial of _____
_____ 2003-
present. Principal Investigator.

Phase III, randomized, double-blind, multi-center study to evaluate the safety and efficacy of

_____ 2003-present.
Principal Investigator.

Phase III, randomized, double-blind, multi-center study to evaluate the safety and efficacy of

_____ 2003-present.
Principal Investigator.

_____ 2000-2004. Principal Investigator.

ARTEMIS Global Antifungal Surveillance Program. University of Iowa, 2001-2004.
Principal Investigator.

Device-specific infections in long-term care and effectiveness of targeted infection control
practices. VERAM. 2002-2004. Co-investigator. _____ , Principal Investigator.

Trends in *Candida glabrata* susceptibilities to anti-fungal agents in a Tertiary Care Medical
Center, 2002-2004. Co-Principal Investigator with _____ , Pharm D.

A randomized controlled trial of _____

_____, 2003-2004, Co-Investigator. _____ Principal
Investigator.

Ongoing

Trial of varicella vaccine for the prevention of herpes zoster and its complications. VA
Cooperative Study, 1998-present, Principal Investigator.

Surveillance of invasive fungal infections in bone marrow/stem cell and solid organ transplantation recipients: A prospective, multi-center study. Centers for Disease Control and Prevention, 2001-present. Principal Investigator.

International Collaborative Study of Infectious Endocarditis. 2001-present. Co-investigator. _____, Principal Investigator.

OPTIMA: Options in management with antiretrovirals. VA Cooperative Study. 2001-present. Co-investigator. Sandro Cinti, Principal Investigator.

A phase I/II randomized, placebo-controlled trial to assess the safety and efficacy of intravenous immunoglobulin G (OMR-IGG-AM™) containing high anti-West Nile Virus antibody titers in patients with, or at high risk for progression to West Nile Virus encephalitis and/or myelitis. NIAID Collaborative Antiviral Study Group, 2003-present. Principal Investigator.

Investigation of the natural history of West Nile Virus infection in patients with or at risk for progression to West Nile Virus encephalitis and/or myelitis. NIAID Collaborative Antiviral Study Group 2003-present, Principal Investigator.

Open label, limited access protocol of _____, 2003-present, Principal Investigator.

Occurrence of adverse events in elderly versus younger patients receiving home intravenous antimicrobial therapy. _____ 2003-present, Principal Investigator.

Invasive fungal infections (IFI) surveillance initiative. _____, 2004-present, Principal Investigator.

_____, 2004-present, Principal Investigator.

_____, 2004-present. Co-Investigator, _____ Pharm D., Principal Investigator.

A randomized double-masked trial of caspofungin versus placebo as prophylaxis of invasive candidiasis in high-risk adults in the critical care setting. NIAID, Merck, Inc., 2004-present, Principal Investigator.

Translating infection prevention evidence into practice. AHRQ/VA, 2004-present. Co-Investigator, Sanjay Saint, M.D., Principal Investigator.

Transplant associated infection surveillance network. CDC, 2004-present, Principal Investigator.

CERTIFICATION AND LICENSURE

Certification: American Board of Internal Medicine, 1972

Licensure: Michigan, 1969

HONORS AND AWARDS

Student

Rollo E. McCotter Award, 1966

Carl V. Weller Award in Pathology, 1967

Roche Award, 1967

Dean's Award, 1966, 1967, 1969

Pfizer Scholarship, 1968

Janet Glasgow Award, 1969

Valedictorian, University of Michigan Medical School, 1969

Faculty

Elizabeth C. Crosby Award for Excellence in Basic Science Teaching, 1980, 1992, 1994, 2000

Silver Shovel Award for Excellence in Teaching, 1982

Kaiser Permanente Award for Excellence in Clinical Teaching, 1982

Faculty Recognition Award, University of Michigan, 1982

Sophomore Medical Student Teaching Award, 1986, 1987, 1988, 1989, 1990, 1991

AMWA Gender Equity Award, 1995, 1998

Medical Student Award for Teaching Excellence, 1998

Richard D. Judge Award for Medical Student Teaching, 1999

Medical School Class of 2005 Award for Excellence in Teaching, 2002

MEMBERSHIPS AND OFFICES IN PROFESSIONAL SOCIETIES

Society for Leukocyte Biology (Reticuloendothelial Society), 1971 - 2000

American Society of Microbiology, 1972 - Present

American Federation for Clinical Research, 1972 - Present

American College of Physicians, 1973 - 1977

Fellow, 1977 - Present

Sigma Xi, 1974 - Present

American Association of Immunologists, 1975 - 1998

American Association for Advancement of Science, 1976 - Present

Central Society for Clinical Research, 1978 - Present

Infectious Diseases Council, 1983 - 1986

Chairperson, Infectious Diseases Council, 1986

Infectious Diseases Society of America, Fellow, 1978 - Present

Central Clinical Research Club, 1981 - 1984

Medical Mycological Society of the Americas, 1981 - Present

American Geriatrics Society, 1985 - Present

Veterans Affairs Society of Practitioners in Infectious Diseases, 1986 - Present

Secretary, 1990-1992

President, 1992-1994

Society of Hospital Epidemiologists of America, 1986 – Present

Fellow, 2004-present

International Society Human/Animal Mycology, 1988 - Present

International Immunocompromised Host Society, 1990 - Present

Co-Chair, Section on Aging, Infections, and Immunity, 1992

Councillor: 1996-1998

Vice-President: 1998-2000

President-Elect: 2000-2002

President, 2002-2004

European Society of Clinical Microbiology and Infectious Diseases, 1997 - Present

International Association of Physicians for AIDS Care, 1997- 2002

Alliance for the Prudent Use of Antibiotics, 2000 – present

Honor Societies

Alpha Epsilon Delta

Iota Sigma Pi

Phi Kappa Phi

Alpha Omega Alpha

TEACHING ACTIVITIES

University

Director, Inteflex Clinical Studies (Infectious Diseases), University of Michigan Medical School, 1979 - 1982

Director, Clinical Clerkships, Department of Internal Medicine, University of Michigan Medical School, 1980 - 1985

Sequence Director, Introduction to Clinical Sciences, (Infectious Diseases), University of Michigan Medical School, 1987 - 1992

Coordinator, Preventive Medicine Sequence on AIDS, University of Michigan Medical School, 1990 - 1992

Sequence Coordinator, Infectious Diseases/Microbiology Sequence. University of Michigan Medical School, 1992 - Present


Graduate Students

Dissertation Advisor for Ph.D. Thesis, _____ Department of Physiology, University of Michigan, 1981 - 1983


Post-doctoral Fellowship Director, _____

Dissertation Committee, Masters Thesis. _____ Department of Biology, Eastern Michigan University, 1993 - 1995

Resident Research Projects



Student Research Projects



EXTRAMURAL INVITED PRESENTATIONS

The Azole Antimycotics. Focus on Fungal Infections, VII. San Antonio, March 1997.

Resistance to Antifungal Agents. New and Re-Emerging Infectious Diseases. CDC, National Foundation for Infectious Diseases, and Emory University School of Medicine, Atlanta, GA, May 1997.

MRSA: A Pathogen of Hospitals, Long-Term Care Facilities, and the Community. East Tennessee State University, April 1997.

Candidiasis - New Developments in Epidemiology and Treatment. Duke University Medical Center, April 1997.

New Developments in the Epidemiology of Candidiasis. Mayo Clinic, April 1997.

Antibiotic Use and Resistance in Nursing Homes. European Congress Clinical Microbiology and Infectious Diseases, Lausanne, Switzerland, May 1997.

New Developments in the Diagnosis of Endemic Mycoses. 13th Congress of the International Society for Human and Animal Mycology, Parma, Italy, June 1997.

Infectious Diseases-Geriatrics Core Curriculum on Common Diseases, Disorders, and Health Concerns. Am Geriatrics Soc, Atlanta, GA, May 1997.

Antifungal Drugs for the New Millennium. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September, 1997.

Fungal Infections in HIV Infected Patients. Topeka, KS, October 1997.

Invasive Candidiasis and Aspergillosis. American Society of Health Systems Pharmacists, Atlanta, GA, December 1997.

Antifungal therapy. Martin Luther King Hospital, Charles Drew Medical Center, Los Angeles, CA, November 1997.

Antibiotic Resistance in Long-Term Care. Am Soc Microbiology, Southern California Branch, November 1997.

Management and Prevention of Severe Candidal Infections. l'Universite Laval, Montreal, Quebec, March 1998.

Diagnosis and Management of Candidal Infections in the ICU. Montreal General Hospital, Quebec City, Quebec, March 1998.

International Consensus on the Management and Prevention of Severe Candidal Infections. McGill University, Montreal, Quebec, March 1998.

Management of Candidal Infections in the ICU. Royal Victoria Hospital, Montreal, Quebec, March 1998.

Advances in the Diagnosis and Treatment of Systemic Fungal Infections. Australasian Society for Infectious Diseases, Hobart, Tasmania, April 1998.

Management of Nosocomial Fungal Infections. St. Michael's Hospital, Toronto, Ontario, May, 1998.

Management of Fungal Infections in the ICU. The Wellsley Central Hospital, Toronto, Ontario, May 1998.

An Update on the Treatment of Fungal Infections. West Penn Medical Center, Pittsburgh, PA, May 1998.

Candida Update. LSU/Our Lady of the Lake Regional Medical Center, Baton Rouge, LA, June 1998.

Vancomycin-Resistant Enterococci. Symposium on Multidrug Resistant Bacteria in Long-Term Care Facilities. Am Geriatrics Soc Annual Meeting, May 1999.

Treatment of Fungal Infections in Immunocompromised Patients. Symposium on Current Treatment of Severe Infections, Helsinki, Finland, May 1999.

- Epidemiology and Treatment of Candidiasis. Annual Delaware Infectious Diseases Symposium, November 1999.
- New Aspects of the Epidemiology and Treatment of Candidemia. University of Texas Southwestern Medical Center, Dallas, April 2000.
- Impact of HAART on Management of Endemic Mycoses. International Society of Human and Animal Mycology, Buenos Aires, May 2000.
- Candiduria. International Society of Human and Animal Mycology, Buenos Aires, May 2000.
- New drugs to Treat Systemic Mycotic Infections. New and Re-emerging Infectious Diseases, National Foundation for Infectious Diseases, Atlanta, June 2000.
- Fungal Infections in HIV Infected Patients. Northwestern University Medical Center, Chicago, June 2000.
- Guidelines for Treating Fungal Infections. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 2000.
- Candiduria. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 2000.
- Nosocomial Fungal Infections. Duke University Medical Center, November 2000.
- Current Issues in the Prophylaxis and Treatment of Nosocomial Fungal Infections. Contemporary Issues in Nosocomial Fungal Infections, National Foundation for Infectious Diseases Symposium, Toronto, March 2001.
- Epidemiology of Susceptible and Resistant *Staphylococcus Aureus* Infections. 3rd Annual Symposium on Gram positive cocci, New York City, April 2001.
- New Antifungal Agents. Infectious Diseases Grand Rounds, Stony Brook Medical Center, New York, May 2001.
- New Aspects of the Epidemiology and Treatment of *Candida* Infections. Grand Rounds University of Iowa Medical Center, May 2001.
- Infections in Long-Term care Facilities. Fourth Annual Update in Infectious Diseases, University of Iowa, Galena, IL, May 2001.
- Candiduria. Grand Rounds, Harbor UCLA Medical Center, May 2001.
- New Aspects of Endemic Mycoses, New Orleans City-Wide Infectious Diseases Conference, June 2001.
- New Aspects of the Epidemiology and Treatment of *Candida* Infections. 23rd Annual Infectious Diseases and Antibiotic Therapy Conference, Orlando, July 2001.
- New Antifungal Agents. Infectious Diseases Conference, Rochester General Hospital, Rochester, NY, October 2001.
- MSG Guidelines for Treatment of Invasive Candidiasis, 6th Annual Trends in Invasive Fungal Infections, Prague, Czech Republic, October 2001.

Candidiasis: Epidemiology, Diagnosis, and Treatment, Internal Medicine Grand Rounds, Long Island Jewish Medical Center, NY, November 2001.

Update on Epidemiology and Treatment of Systemic Fungal Infection. Infectious Diseases Update: 2001, Wilmington, DE, November 2001.

Fungal Infections in Travelers. 2nd Annual Fungal Infections Congress, Paris, France, November 2001.

Scedosporium/Pseudallescheria Infections. Focus on Fungal Infections 12, Phoenix, AZ, March 2002.

Therapeutic and Preventive Options for Management of VRE Infections. Vancomycin Resistant Enterococcal Infections: A Clinical Challenge. European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, April 2002.

Update in Treatment of Fungal Infections. Cleveland Clinic, July 2002.

Approaches to the Evolving Antifungal Armamentarium. 42nd Interscience Conference on Antimicrobial Agents & Chemotherapy, San Diego, September 2002.

New Antifungal Agents. Critical Care/Infectious Diseases Combined Conference, Wayne State University Medical Center, Detroit, MI, September 2002.

Update on New Antifungal Drugs. Grand Rounds, Easton Hospital, Easton, PA, October 2002.

Update on New Antifungal Therapy. ID Grand Rounds, Henry Ford Hospital, Detroit, MI, October 2002.

Fungal Infections in Cancer Patients. Comprehensive Cancer Center, Indianapolis, IN, October 2002.

Medical Progress and the Upsurge in Fungal Infections. Veterans Affairs Healthcare System of Ohio, Dayton, Ohio, November 2002.

Update on Fungal Infections. Department of Internal Medicine Grand Rounds, University of Nebraska, Omaha, NE, November 2002.

New Developments in Treatment of Fungal Infections. Infectious Diseases Grand Rounds, Case Western Reserve Medical Center, Cleveland, Ohio, December 2002.

Candidemia and Use of New Antifungal Agents. Department of Internal Medicine Grand Rounds, Monterey Community Hospital, Monterey, CA, December 2002.

New Antifungal Agents. Department of Internal Medicine Grand Rounds, University of Tennessee, Memphis, TN, January 2003.

Antifungal Therapy. Medical Grand Rounds, Boise Veteran Affairs Department of Internal Medicine Center, Boise, ID, January 2003.

Advances in Antifungal Therapy. Department of Internal Medicine Grand Rounds, Northwestern University Department of Internal Medicine Center, Chicago, IL, April 2003.

Nosocomial Fungal Infections. Department of Internal Medicine Grand Rounds, University of Kentucky Department of Internal Medicine Center, Lexington, KY, April 2003.

New Antifungals – When are They Indicated? Department of Internal Medicine Grand Rounds, Akron City Hospital, Akron, OH, April 2003.

Fungal Infections in Neutropenic Patients. American Thoracic Society Annual Meeting, Seattle, WA, May 2003.

Fungal Infections in Elderly Patients. Dayton Society of Internal Medicine, May 2003.

Update on Antifungal Therapy. 40th Annual William J. Holloway Infectious Diseases Conference, Wilmington, DE, May 2003.

Management of Systemic Mycotic Infections in the era of Antifungal Resistance. NFID/Cleveland Clinic Infectious Diseases Course, Cleveland, OH, June 2003.

New Antifungals: Where, When, and How. 41st Annual Infectious Diseases Society of America, San Diego, CA, October 2003.

Fungal Infections in Older Adults. MD Anderson Cancer Center, Houston, TX, January 2004.

New Antifungal Agents. Medical Grand Rounds, Mercy Medical Center, Pittsburgh, PA, February 2004.

Sporotrichosis. Focus on Fungal infections 14. New Orleans, LA, March 2004.

New Antifungal Agents. St. Louis Infectious Diseases Society, St. Louis, MO, March 2004.

Fungal Infections in Older Adults. Medical Grand Rounds, New York Hospital, Queens, NY, September 2004.

Update on Antifungal Therapy. Medical Grand Rounds, Medical College of Ohio, Toledo, OH, November 2004.

Update on Fungal Infections. Medical Grand Rounds, Temple University Medical Center, Philadelphia, PA, December 2004.

COMMITTEE AND ADMINISTRATIVE SERVICE

National and International

Member, Infectious Diseases Field Advisory Group, Department of Veterans Affairs, Washington D.C., 1987 - Present

Member, Task Force on Women in Infectious Diseases, Infectious Diseases Society of America, 1992 - 1994

Member, Publications Committee, Infectious Diseases Society of America, 1993 - 1996

Member, Infection Control Advisory Group, Department of Veterans Affairs, Washington, DC, 1993 - 1996

Member, Pneumococcal Basic Science, Clinical Trials, and Efficacy Planning Group, Institute for Advanced Studies in Immunology and Aging, 1997

American Federation of Aging Research. (AFAR) Research Committee, 2002 – 2003.

Veterans Affairs Medical Center

Chairperson, Infection Control Committee, Ann Arbor Veterans Affairs Medical Center, 1977 - Present

Member, Pharmacy and Therapeutics Committee, Ann Arbor Veterans Affairs Medical Center, 1977 - 1986

Member, Drug Utilization Review Committee, VA Regional Planning Committee, 1984

Member, Acute Care Geriatric Planning Committee, VA Regional Planning Committee, 1984.

Chairperson, District 14 AIDS Task Force, 1987 – 1989

Member, Regional AIDS Advisory Group, 1987

Chairperson, AIDS Support Team, Ann Arbor Veterans Administration Medical Center, 1987

Human Studies Subcommittee, Ann Arbor Veterans Affairs Medical Center, 1994 - 1997
Chairperson, 1995-1997

Consultant, Infection Control Committee, Saginaw VA Medical Center, 1999 – 2002

Member, Dean's Committee, 2001 – present

Chairperson, Human Studies Subcommittee, Ann Arbor Veteran Affairs Medical Center, 2002 - present

University

Member, Internship Selection Committee, Department of Internal Medicine, University of Cincinnati Medical School, 1974 - 1977

Member, Clinical Phase Committee, University of Michigan Medical School, 1980 - 1985
Chairperson, 1983-1985

Member, Psychiatry Review and Search Committee, University of Michigan Medical School, 1981

Member, Resident Evaluation Committee, Department of Internal Medicine, University of Michigan Medical School, 1983 - 1985

Member, Academic Affairs Council, University of Michigan Medical School, 1984 - 1987
Chairperson, 1984-1986


Member, Committee on Promotions and Tenure, Department of Internal Medicine, University of Michigan Medical School, 1984 - 1987

Member, Admissions Committee, University of Michigan Medical School, 1984 - 1985

Member, Task Force on AIDS, University of Michigan Medical School, 1986

Member, Committee on Use and Care of Animals, University of Michigan, 1987 - 1990

Member, Academic Program Advisory Committee, University of Michigan Medical School, 1989 - 1990



Member, Planning Committee, Internal Medicine Update, 1997 – 2000

Chair, Infectious Diseases, Microbiology, Host Defenses Curriculum. Curriculum Design Task Force, 2002 – present.

**APPEARS THIS WAY
ON ORIGINAL**

BIBLIOGRAPHY**PEER REVIEWED PUBLICATIONS:**

1. Murphy WH, Tam MR, Lanzi RL, Abell MR, and Kauffman CA: Age dependence of immunologically induced central nervous system disease in C58 mice. *Cancer Res* 30:1612-1622, 1970.
2. Kauffman CA, Watanakunakorn C, and Phair JP: Pneumococcal pericarditis: A continuing problem in the antibiotic era. *Am J Med* 54:743-750, 1973.
3. Tan JS, Strauss RG, Akabutu J, Kauffman CA, Mauer AM, and Phair JP.: Persistent neutrophil dysfunction in an adult: Combined defect in chemotaxis phagocytosis and intracellular killing. *Am J Med* 57: 251-258, 1974.
4. Kauffman CA and Tan JS: *Torulopsis glabrata* renal infection. *Am J Med* 57:217-224, 1974.
5. Kauffman CA, Phair JP, Linnemann CC Jr, and Schiff GM: Cell-mediated immunity in humans during viral infection. I. Effect of rubella on dermal hypersensitivity, phytohemagglutinin response, and T lymphocyte numbers. *Infect Immun* 10:212-215, 1974.
6. Kauffman CA, Linnemann CC Jr, Tan JS, Schiff GM, and Phair JP: Cell-mediated immunity in humans during viral infection. II. Dermal hypersensitivity and *in vitro* lymphocyte proliferation during mild viral respiratory infection. *Infect Immun* 10:757-761, 1974.
7. Linnemann CC Jr, Kauffman CA, Shea L, Schiff GM, Partin JC and Schubert WK: The association of Reye's syndrome with viral infection. *Lancet* 2:179-182, 1974.
8. Sieving R, Kauffman CA, and Watanakunakorn C: Deep fungal infection in systemic lupus erythematosus: Report of three cases and review of the literature. *J Rheumatol* 2:61-72, 1975.
9. Kauffman CA, Manzler AD, and Phair JP: Cell-mediated immunity in patients on long-term hemodialysis. *Clin Exper Immunol* 22:54-61, 1975.
10. Picardi JL, Kauffman CA, Schwarz J, Holmes J, Phair JP and Fowler NO: Pericarditis caused by *Histoplasma capsulatum*: Report of sixteen cases and review of the literature. *Am J Cardiol* 37:82-88, 1976.
11. Kauffman CA, Linnemann CC Jr, Schiff GM, and Phair JP: The effect of viral and bacterial pneumonias on cell-mediated immunity in humans. *Infect Immun* 13:78-83, 1976.
12. Kauffman CA, Carleton JA, and Frame PT: A simple assay for 5-fluorocytosine in the presence of amphotericin B. *Antimicrob Agents Chemother* 9:381-383, 1976.
13. Picardi JL, Kauffman CA, Schwarz J, and Phair JP: Detection of precipitating antibodies to *Histoplasma capsulatum* by counterimmunoelectrophoresis. *Am Rev Res Dis* 114:171-176, 1976.

14. Baird IM, Slepach JM, Kauffman CA, and Phair JP: Nosocomial infection with gentamicin-carbenicillin resistant *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 10:626-629, 1976.
15. Kauffman CA, Watanakunakorn C, and Phair JP: Pneumococcal arthritis. *J Rheumatol* 3:409-419, 1976.
16. Kauffman CA and Frame PT: Bone marrow toxicity associated with 5-fluorocytosine therapy. *Antimicrob Agents Chemother* 11:244-247, 1977.
17. Schwarz J and Kauffman CA: Occupational hazards from deep mycoses. *Arch Dermatol* 113:1270-1275, 1977.
18. Williams SG and Kauffman CA: The survival of *Streptococcus pneumoniae* in sputum from patients with pneumonia. *J Clin Microbiol* 7:3-5, 1978.
19. Roselle GA, Clyne DH, and Kauffman CA: Carbenicillin nephrotoxicity. *South Med J* 71:84-86, 1978.
20. Kauffman CA, Schiff GM, and Phair JP: Influenza in ferrets and guinea pigs: Effect on cell-mediated immunity. *Infect Immun* 19:547-552, 1978.
21. Kauffman CA, Israel KS, Smith JW, White AC, Scharwz J, and Brooks GF: Histoplasmosis in immunosuppressed patients. *Am J Med* 64:923-932, 1978.
22. Phair JP, Kauffman CA, Bjornson A, Gallagher J, Adams L and Hess EV: Host defenses in the aged: Evaluation of components of the inflammatory and immune response. *J Infect Dis* 138:67-73, 1978.
23. Kauffman CA, Ramundo NC, Williams SG, Dey CR, Phair JP, and Watanakunakorn C: Surveillance of gentamicin-resistant gram-negative bacilli in a general hospital. *Antimicrob Agents Chemother* 13:918-923, 1978.
24. Phair JP, Kauffman CA, and Bjornson AB: Investigation of host defense mechanisms in the aged as determinants of nosocomial colonization and pneumonia. *J Reticuloendothelial Soc* 23:397-406; 1978.
25. Good AE, Hague JM, and Kauffman CA: Streptococcal endocarditis initially seen as septic arthritis. *Arch Intern Med* 138:805-806, 1978.
26. Good AE, Gayes JM, Kauffman CA, and Archer GL: Multiple pneumococcal pyarthrosis complicating rheumatoid arthritis. *South Med J*. 71:502-504, 1978.
27. Watanakunakorn C and Kauffman CA: In vitro susceptibility of gentamicin and/or tobramycin resistant gram-negative bacilli to seven aminoglycosides. *Infection* 6:111-115, 1978.
28. Roselle GA and Kauffman CA: Amphotericin B and 5-fluorocytosine: In vitro effects on lymphocyte function. *Antimicrob Agents Chemother* 14:398-402, 1978.
29. Phair JP, Kauffman CA, Bjornson AB, Adams LE, and Linnemann CC Jr.: Failure to respond to influenza vaccine in the aged. Correlation with B-cell number and function. *J Lab Clin Med* 92:822-828, 1978.

30. Linnemann CC Jr, Kauffman CA, First MR, Schiff GM, and Phair JP: The humoral and cellular immune response to cytome-galovirus infection after renal transplantation. *Infect Immun* 22:176-180, 1978.
31. Roselle GA and Kauffman CA: Invasive pulmonary aspergillosis in a nonimmunosuppressed patient. *Am J Med Sci* 276:357-362, 1978.
32. Phair JP, Kauffman CA, Jennings R, and Potter CW: Influenza infections in the guinea pig: Immune response and resistance. *Med Microbiol Immunol* 165:241-254, 1979.
33. Allo MD, Silva J, Kauffman CA, and Dicks R: Enlarging histoplasmosis following treatment of meningitis due to *Histoplasma capsulatum*. *J Neurosurg* 51:242-244, 1979.
34. Kauffman CA and St. Hilaire RJ: Salmonella meningitis: Occurrence in an adult. *Arch Neurol* 36:578-580, 1979.
35. Silva J, Kauffman CA, Simon DG, Landrigan PH, Humphrey HEB, Heath CW, Wilcox KR, Van Amburg G, Kaslow RA, Ringel A, and Hoff K: Lymphocyte function in humans exposed to polybro-minated biphenyls. *J Reticuloendothelial Soc* 26:341-347, 1979.
36. Kauffman CA Linnemann CC Jr and Alvira M: Cytomegalovirus encephalitis associated with thymoma and immunoglobulin deficiency. *Am J Med* 67:724-728, 1979.
37. Kauffman CA, Bergman AG, and Hertz CS: Antimicrobial resistance of Haemophilus species in patients with chronic bronchitis. *Am Rev Respir Dis* 120:1382-1385, 1979.
38. Kauffman CA and Severance PJ: Nosocomial cryptococcal infection. *South Med J* 73:267, 1980.
39. Williams ME and Kauffman CA: Transfer factor: A murine model. *Infect Immun* 27:187-191, 1980.
40. Roselle GA and Kauffman CA: Amphotericin B and 5-fluorocytosine: Effects on cell-mediated immunity. *Clin Exper Immunol* 40:186-192, 1980.
41. Severance PJ, Kauffman CA, and Sheagren IN: Rapid identification of *Staphylococcus aureus* using lysostaphin sensitivity. *J Clin Microbiol* 11: 724-727, 1980.
42. Severance PJ, Kauffman CA, and Sheagren IN: Lysostaphin sensitivity of staphylococci: Effect of various blood culture media. *J. Clin Microbiol* 12:709-710, 1980.
43. Kauffman, CA, Bergman AG, Severance PJ, and McClatchey KD: Detection of cryptococcal antigen: Comparison of two latex agglutination tests. *Am J Clin Pathol* 75:106-109, 1981.
44. Lynch JP, Schaberg DR, Kissner DG, and Kauffman CA: *Cryptococcus laurentii* lung abscess. *Am Rev Respir Dis* 123:135-138, 1981.
45. Kauffman CA, Shea MJ, and Frame PT: Invasive fungal infections in patients with chronic mucocutaneous candidiasis. *Arch Intern Med* 141:1076-1078, 1981.
46. Kauffman CA: Cell-mediated immunity in ferrets: Delayed dermal hypersensitivity, lymphocyte transformation, and macrophage migration inhibitory factor production. *Develop Compar Immunol* 5:125-134, 1981.

47. Kauffman CA, Slama TG, and Wheat LJ: *Histoplasma capsulatum* epididymitis. J Urology 125:434-435, 1981.
48. Kauffman CA and Bergman AG: Lymphocyte subpopulations in the ferret. Develop Compar Immunol 5:671-678, 1981.
49. Kauffman, CA, Severance PJ, Silva J and Huard TK: Neutropenia associated with vancomycin therapy. South Med J 75:1131-1132, 1982.
50. Kauffman CA, Bergman AG, and O'Connor RP: Distemper virus infection in ferrets: An animal model for measles-induced immunosuppression. Clin Exper Immunol 47:617-625, 1982.
51. Severance PJ and Kauffman CA: Diagnosis of cryptococcosis: Comparison of various methods to detect *Cryptococcus neoformans*. Mykosen 26:29-33, 1982.
52. Stockstill MT and Kauffman CA: A comparison of tuberculous and cryptococcal meningitis. Arch Neurol 40:81-85, 1983.
53. Wilson KH and Kauffman CA: Persistent *Strongyloides stercoralis* in a blind loop of bowel: Successful treatment with mebendazole. Arch Intern Med 143: 357-358, 1983.
54. Kauffman CA, Liepman MK, Eergnan AG, and Mioduszewski J: Trimethoprim sulfamethoxazole prophylaxis in neutropenic patients: Reduction of infection and effect on bacterial and fungal flora. Am J Med 74:599-607, 1983.
55. Kauffman CA, Hertz CS, and Sheagren IN: *Staphylococcus saprophyticus*: Role in urinary tract infections in men. J Urology 130:493-494, 1983.
56. McGuire NM, Kauffman CA, Hertz CS and Kovach JM: Detection of bacteremia: Evaluation of the EACTEC antimicrobial removal system. J Clin Microbiol 18:449-451, 1983.
57. Jones PG, Kauffman, CA, McAuliffe MS, Liepman MK, and Bergman AG: Efficacy of ketoconazole versus nystatin for the prevention of fungal infections in neutropenic patients. Arch Intern Med 144:549-551, 1984.
58. Kauffman CA, Jones PG, Bergman AG, McAuliffe LS, and Liepman MK: Effect of prophylactic ketoconazole and nystatin on fungal flora. Mykosen 27:165-172, 1984.
59. Jones PG, Kauffman CA, Kluger MJ, Hayes C, Bergman AG, and Cannon JG: Fever in the elderly: Production of leukocytic pyrogen by monocytes from elderly person. Gerontology 30:182-187, 1984.
60. Liepman MK, Jones PG, and Kauffman CA: Endocarditis in leukemic patients with right atrial catheters. Cancer 54:804-807, 1984.
61. Deery HG, Kauffman CA, Fekety FR, Jones PG, Silva J, Sell TL and Supena RE: Effect of therapy with moxalactam on carriage of *Clostridium difficile*. J Antimicrob Chemother 13:521-524, 1984.
62. Kauffman CA, Sheagren IN, and Quie PG: *Staphylococcus epidermidis* mediastinitis and disseminated intravascular coagulation. Ann Intern Med 101:60-61, 1984.
63. Bergman AG and Kauffman CA: Dermatitis due to *Sporobolomyces* infection. Arch Dermatol 120:1059-1060, 1984.

64. Kauffman CA, Wilson KH, and Schwartz DB: Necrotizing pulmonary aspergillosis with oxalosis. *Mykosen* 11:535-538, 1984.
65. McGuire NM, Port FK, and Kauffman CA: Ketoconazole pharmaco-kinetics in continuous ambulatory peritoneal dialysis. *Peritoneal Dialysis Bull* 4:199-201, 1984.
66. Tocco-Bradley R, Kluger MJ, and Kauffman CA: Effect of age on fever and acute phase response of rats to endotoxin and *Salmonella typhimurium*. *Infect Immun* 47:106-111, 1985.
67. Wilson KH and Kauffman CA: Oral antibiotic therapy of osteo-myelitis of the foot in diabetic patients. *South Med J* 78:223-224, 1985.
68. Barg NL, Kish MA, Kauffman CA, and Supena RB: Group A streptococcal bacteremia in an urban hospital. *Am J Med* 78:569-574, 1985.
69. McGuire NM and Kauffman CA: Septic arthritis in the elderly. *J Am Geriatric Soc* 33:170-174, 1985.
70. Tocco-Bradley R, Singer R, Kluger MJ, and Kauffman CA: Effect of age on the febrile response of rats to endogenous pyrogen. *Gerontology* 31:349-354, 1985.
71. Jones PG, Kauffman CA, Port FK, and Kluger MJ: Fever in uremia: Production of leukocytic pyrogen by chronic dialysis patients. *Am J Kidney Dis* 6:241-244, 1985.
72. NIAID Mycoses Study Group: Treatment of blastomycosis and histoplasmosis with ketoconazole: Results of a prospective randomized clinical trial. *Ann Intern Med* 103:861-872, 1985.
73. Kauffman CA: Endogenous pyrogen/Interleukin-1 production in aged rats. *Exper Gerontol* 21:75-78, 1986.
74. Kauffman CA, Jones PG, and Kluger MJ: Fever and malnutrition: Endogenous pyrogen/interleukin-1 production in malnourished patients. *Am J Clin Nutrition* 44:449-452, 1986.
75. Kauffman CA and Jones PG: Candidiasis: Diagnostic and therapeutic challenge. *Postgrad Med* 80:129-134, 1986.
76. Bradley SF, Kluger MJ, and Kauffman CA: Age and protein malnutrition: Effects on the febrile response. *Gerontology* 33:99-109, 1987.
77. Bacon AE, Jorgensen KA, Wilson KH and Kauffman CA: Emergence of nosocomial methicillin-resistant *Staphylococcus aureus* and therapy of colonized personnel during a hospital wide outbreak. *Infect Control* 8:145-150, 1987.
78. Zervos MJ, Kauffman CA, Therasse PM, Bergman AG, Mikesell TS and Schaberg DR: Nosocomial infection by gentamicin-resistant *Streptococcus faecalis*: An epidemiologic study. *Ann Intern Med* 106:687-691, 1987.
79. Bradley SF, Wilson KH, Rosloniec MA, and Kauffman CA: Recurrent pseudobacteremias traced to a radiometric blood culture device. *Infect Control* 8:281-283, 1987.
80. NIAID Mycoses Study Group: Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. *N Engl J Med* 317:334-341, 1987.

81. NIAID Mycoses Study Group: Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. *Am J Med* 83:236-242, 1987.
82. Terpenning MA, Buggy BP, and Kauffman CA: Infective endocarditis: Clinical features in young and elderly patients. *Am J Med* 83:626-634, 1987.
83. Zervos MJ, Terpenning MS, Schaberg DR, Therasse PM, Medendorp SV, and Kauffman CA: High-level aminoglycoside resistant enterococci: Colonization of nursing home and acute care hospital patients. *Arch Intern Med* 147:1591-1594, 1987.
84. Shadomy HJ, Wood-Helie S, Shadomy S, Dismukes WE, Chau RY, and Mycoses Study Group: Biochemical serogrouping of clinical isolates of *Cryptococcus neoformans*. *Diagnostic Microbiol Infect Dis* 6:131-136, 1987.
85. Bradley SF, McGuire NM, and Kauffman CA: Sino-orbital aspergillosis: Cure with medical therapy. *Mykosen* 30:379-385, 1987.
86. Zervos MJ, Patterson JE, Edberg S, Pierson C, Kauffman CA, Mikesell T, and Schaberg DR: A single concentration broth microdilution test for the detection of high level aminoglycoside resistance in enterococci. *J Clin Microbiol* 25:2443-2444, 1987.
87. Bradley SF and Kauffman CA: The effect of protein malnutrition on interleukin-1 production in the Fischer rat. *J Leuk Biol* 43:36-40, 1988.
88. Zervos MJ, Bacon AE, Schaberg DR, and Kauffman CA: Entero-coccal superinfection in patients treated with ciprofloxacin. *J Antimicrob Chemother* 21:113-116, 1988.
89. Bradley SF and Kauffman CA: The effect of protein malnutrition on salmonellosis and fever. *Infect Immun* 56:1000-1002, 1988.
90. Kauffman CA and Terpenning MS: Deep fungal infections in the elderly. *J Am Geriatric Soc* 36:548-557, 1988.
91. Leavitt AD and Kauffman CA: Cryptococcal aortitis. *Am J Med* 85:108-110, 1988.
92. Terpenning MA, Buggy BP, and Kauffman CA: Hospital-acquired infective endocarditis. *Arch Intern Med* 148:1601-1603, 1988.
93. Patterson JE, Masecar BL, Kauffman CA, Schaberg DR, Hierholzer WJ, and Zervos MJ: Gentamicin resistance plasmids of enterococci from diverse geographic areas are heterogeneous. *J Infect Dis* 158:212-216, 1988.
94. Kaatz GW, Gitlin SD, Schaberg DR, Wilson KJ, Kauffman CA, Sea SM, and Fekety FR: Acquisition of *Clostridium difficile* from the hospital environment. *Am J Epidemiol* 127:1289-1294, 1988.
95. Robert ME and Kauffman CA: Blastomycosis presenting as polyarticular septic arthritis. *J Rheumatol* 15:1438-1442, 1988.
96. Terpenning MS, Zervos MJ, Schaberg DR, and Kauffman CA: Enterococcal infections: An increasing problem in hospitalized patients. *Infect Control Hosp Epidemiol* 9:457-461, 1988.
97. Bulo AN, Bradley SF, and Kauffman CA: Susceptibility of yeast-like fungi to a new antifungal agent, LY 121019. *Mycoses* 31:330-333, 1988.

98. Lesperance M, Baumgartner D, and Kauffman CA: Arthritis due to *Sporothrix schenckii*. *Mycoses* 31:599-603, 1988.
99. Fekety R, Silva J, Kauffman CA, Buggy BP, and Deery HG: Treatment of *Clostridium difficile* antibiotic associated colitis with oral vancomycin: Comparison of two dosage regimens. *Am J Med* 86:15-19. 1989.
100. Bradley SF, Vibhagool A, Kunkel SL, and Kauffman CA: Monokine secretion in aging and protein malnutrition. *J Leuk Biol* 45:510-514, 1989.
101. Bulo AN, Bradley SF, and Kauffman CA: The effect of cilofungin (LY 121019) in combination with amphotericin B or flucytosine against *Candida* species. *Mycoses* 32:151-157, 1989.
102. Terpenning MS, Allada R, and Kauffman CA: Intermittent urethral catheterization in the elderly. *J Am Geriatrics Soc.* 37:411-416, 1989.
103. Daly AL, Velazquez LA, Bradley SF, and Kauffman CA: Mucormycosis: Association with deferoxamine therapy. *Am J Med* 87:468-471, 1989.
104. Bradley SF and Kauffman CA: Aging and the response to *Salmonella* infection. *Exper Gerontol.* 25:75-80, 1990.
105. Cederna JE, Terpenning MS, Ensberg M, Bradley SF, and Kauffman CA: Eradication of *Staphylococcus aureus* nasal colonization with mupirocin in a nursing home. *Infect Control Hosp Epidemiol* 11:13-16, 1990.
106. Powers KA, Terpenning MS, and Kauffman CA: Prosthetic joint infections in the elderly. *Am J Med.* 88:5-9, 1990.
107. Sangeorzan JA, Bradley SF, and Kauffman CA: Cutaneous manifestations of *Pseudomonas* infection in the acquired immunodeficiency syndrome. *Arch Dermatol.* 126:832-833, 1990.
108. Bradley SF, Vibhagool A, Fabrick S, Terpenning MS, and Kauffman CA: Monokine production by malnourished nursing home patients. *Gerontology* 36:165-170, 1990.
109. Gordon JJ and Kauffman CA: Superinfection with *Streptococcus pneumoniae* during therapy with ciprofloxacin. *Am J Med.* 89:383-384, 1990.
110. Daum T, Schaberg DR, Terpenning MS, Sottile WS, and Kauffman CA: Increasing resistance of *Staphylococcus aureus* to ciprofloxacin. *Antimicrob Agents Chemother* 34:1862-1863, 1990.
111. Patterson TF, Andriole VT, Zervos MJ, Therasse D, and Kauffman CA: The epidemiology of pseudallescheriasis complicating transplantation - nosocomial and community-acquired infection. *Mycoses* 33: 303-310, 1990.
112. Kauffman CA, Bradley SF, and Terpenning MS: Methicillin-resistant *Staphylococcus aureus* in long-term care facilities. *Infect Control Hosp Epidemiol* 11:600-603, 1990.
113. Kauffman CA: Resistance to infection. Minisymposium on Aging, Immunity and Infection. *Aging, Immunol, Infect Dis.*2:181-183, 1990.
114. Bradley SF, Gordon JJ, Baumgartener DD, Marasco WA, and Kauffman CA: Group C streptococcal bacteremia: An analysis of 86 cases. *Rev Infect Dis* 13:270-280, 1991.

115. Sekkarie M, Holmes, C, Ranjit U, and Kauffman CA: Grossly visible fungal colonization of a tenckhoff catheter: A case report and literature review. *Perit Dial Internat* 11:85-87, 1991.
116. Kauffman CA, Bradley SF, Ross SC, and Weber DR: Hepatosplenic candidiasis: Successful treatment with fluconazole. *Am J Med* 91:137-141, 1991.
117. Bradley SF, Terpenning MS, Ramsey MA, Zarins LT, Jorgensen KA, Sottile WA, Schaberg DR, and Kauffman CA: Methicillin resistant *Staphylococcus aureus*: Colonization and infection in a long-term care facility. *Ann Intern Med* 115:417-422, 1991.
118. Crump JRC, Elner SG, Elner VM, and Kauffman CA: Cryptococcal endophthalmitis: A case report and review of the literature. *Rev Infect Dis* 14:1069-1073, 1992.
119. Saag MS, Powderly WG, Cloud GA, and the NIAID Mycoses Study Group and the AIDS Clinical Trials Group: Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. *N. Engl J Med* 326:83-89, 1992.
120. Powderly WG, Saag MS, Cloud GA, and the NIAID AIDS Clinical Trials Group and Mycoses Study Group: A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. *N Engl J Med* 326:793-798, 1992.
121. Triesenberg SN, Clark NM, and Kauffman CA: Group B streptococcal prosthetic joint infection following sigmoidoscopy. *Clin Infect Dis* 15:374-375, 1992.
122. Neitzel S and Kauffman CA: Fever of unknown origin after Angelchick antireflux prosthesis implantation. *Clin Infect Dis*. 15:528-529, 1992.
123. Chenoweth CE, Judd WJ, Steiner EA, and Kauffman CA: Cefotetan-induced immune hemolytic anemia. *Clin Infect Dis*. 15:863-865, 1992.
124. Schaberg DR, Dillon WI, Terpenning MS, Robinson KA, Bradley SF, and Kauffman CA: Increasing resistance of enterococci to ciprofloxacin. *Antimicrob Agents Chemother* 36:2533-2535, 1992.
125. Dismukes WE, Bradsher RW, Cloud GC, Kauffman CA, Chapman SW, George RB, Stevens DA, Girard WM, Saag MS, Bowles-Patton C, and NIAID Mycoses Study Group: Itraconazole therapy of blastomycosis and histoplasmosis. *Am J Med* 93:489-497, 1992.
126. Kauffman CA and Bagnasco FA: Digoxin toxicity associated with itraconazole therapy. *Clin Infect Dis* 15:886-887, 1992.
127. Kauffman CA: Use of the new oral azole antifungal drugs. *Infect in Med* 9:13-18, 1992.
128. Braun DK and Kauffman CA: *Rhodotorula fungemia*: Life-threatening complication of indwelling central venous catheters. *Mycoses* 35:305-308, 1992.
129. Mulligan ME, Murray-Leisure KA, Ribner BS, Standiford HC, John JF, Korvick JA, Kauffman CA, and Yu VL: Methicillin-resistant. *Staphylococcus aureus*: A consensus review of the microbiology, pathogenesis and epidemiology with implications for prevention and management. *Am J Med* 94:313-328, 1993

130. Kauffman CA, Terpenning MS, He X, Zarins LT, Ramsey MA, Jorgensen KA, Sottile WS, and Bradley SF: Attempts to eradicate methicillin-resistant *Staphylococcus aureus* from a long-term care facility with the use of mupirocin ointment. *Am J Med* 94:371-378, 1993.
131. Kauffman CA, Bradley SF, and Vine AK: *Candida* endophthalmitis associated with intraocular lens implantation. Efficacy of fluconazole therapy. *Mycoses* 36:13-17, 1993.
132. Sharkey-Mathis PK, Kauffman CA, Graybill JR, Stevens D, Hostetler JS, Cloud GA, Dismukes WE, and NIAID Mycoses Study Group: Treatment of sporotrichosis with itraconazole. *Am J Med* 95:279-285, 1993.
133. Janssen DA, Zarins LT, Schaberg DR, Bradley SF, Terpenning MS, and Kauffman CA: Detection and characterization of mupirocin resistance in *Staphylococcus aureus*. *Antimicrob Agents Chemother* 37:2003-2006, 1993.
134. Smith KY, Bradley SF, and Kauffman CA: Fever of unknown origin in the elderly: Lymphoma presenting as vertebral compression fractures. *J Am Geriatr Soc* 42:88-92, 1994.
135. Carver RL, Berardi, GR, Knapp MJ, Rider JM, Kauffman CA, Bradley SF, and Atassi M: *In vivo* interaction of ketoconazole and sucralfate in healthy volunteers. *Antimicrob Agents Chemother* 38:326-329, 1994.
136. Boyce JM, Jackson MM, Pugliese G, Batt MD, Fleming D, Garner JS, Hartstein AI, Kauffman CA, Simmons M, Weinstein R, Williams CO, and the AHA Technical Panel: Methicillin-resistant *Staphylococcus aureus* (MRSA): A briefing for acute care hospitals and nursing facilities. *Infect Control Hosp Epidemiol* 15:105-115, 1994.
137. Sangeorzan JA, Bradley SF, He X, Zarins LT, Ridenour GL, Tiballi, RN, and Kauffman CA: Epidemiology of oral candidiasis in HIV infected patients: Colonization, infection, treatment, and emergence of fluconazole resistance. *Am J Med* 97:339-347, 1994.
138. Kauffman CA: New developments in therapy for endemic mycoses. *Clin Infect Dis* 19(Suppl 1):S28-S36, 1994.
139. Harrington GD and Kauffman CA: Cryptic fever due to intramuscular analgesics. *Infect Dis Clin Prac* 3:364-366, 1994.
140. Denning DW, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, Dockery B, Dismukes WE, Stevens DA. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy of invasive aspergillosis. *Am J Med* 97:135-144, 1994.
141. Voice RA, Bradley, SF, Sangeorzan JA, and Kauffman CA: Chronic *Candida* meningitis. An uncommon manifestation of candidiasis. *Clin Infect Dis* 19:60-66, 1994.
142. Harrison MS, Simonte SJ, and Kauffman CA: Trimethoprim-induced meningitis in a patient with acquired immunodeficiency syndrome: Case report and review of the literature. *Clin Infect Dis* 19:431-434, 1994.
143. Kauffman CA: Pneumococcal vaccine use in the elderly: Clinically relevant outcome measures. *Aging, Immunol, Infect Dis* 5:55-60, 1994.

144. Terpenning MS, Bradley SF, Wan JY, Chenoweth CE, Jorgensen KA, and Kauffman CA: Colonization and infection with antibiotic-resistant bacteria in a long-term care facility. *J Am Geriatr Soc* 42:1062-1069, 1994.
145. He X, Tiballi RN, Zarins LT, Bradley SF, Sangeorzan JA, and Kauffman CA: Azole resistance in oropharyngeal *Candida albicans* strains isolated from patients with HIV infection. *Antimicrob Agents Chemother* 38:2495-2497, 1994.
146. Chenoweth CE, Bradley SF, Terpenning MS, Zarins LT, Ramsey MA, Schaberg DR, and Kauffman CA: Colonization and transmission of high-level gentamicin-resistant enterococci in a long-term care facility. *Infect Control Hosp Epidemiol* 15:703-709, 1994.
147. Braun DK, Janssen DA, Marcus J, and Kauffman CA: Cryptococcal infection of a prosthetic dialysis fistula. *Am J Kidney Dis* 24:864-867, 1994.
148. Kauffman CA: Endemic mycoses in older adults. *Infect Dis Clin Prac* 4:41-45, 1995.
149. Prokopowicz GP, Bradley SF, and Kauffman CA: Indolent zygomycosis associated with deferoxamine chelation therapy. *Mycoses* 37:427-431, 1995.
150. Kutas LM, Duggan JM, and Kauffman CA: Pneumococcal vertebral osteomyelitis. *Clin Infect Dis* 20:286-290, 1995.
151. Pappas PG, Bradsher RW, Chapman SW, Kauffman CA, Dine A, Cloud GA, Dismukes WE, and the NIAID Mycoses Study Group: Treatment of blastomycosis with fluconazole. *Clin Infect Dis* 20:267-271, 1995.
152. Bradley SF, Ramsey MA, Morton TM, and Kauffman CA: Mupirocin resistance: Clinical and molecular epidemiology. *Infect Control Hosp Epidemiol* 16:354-358, 1995.
153. Harrington GD, Zarins LT, Ramsey MA, Bradley SF, and Kauffman CA: Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to clindafloxacin. *Diagn Microbiol Infect Dis*. 21:27-31, 1995.
154. Sangeorzan JA, Zervos MJ, Donabedian S, and Kauffman CA: Validity of contour-clamped homogeneous electric field electrophoresis as a typing system for *Candida albicans*. *Mycoses* 38:29-36, 1995.
155. Tiballi RN, He X, Zarins LT, Revankar S, and Kauffman CA: Use of a colorimetric system for yeast susceptibility testing. *J Clin Microbiol* 33:915-917, 1995.
156. Pappas PG, Kauffman CA, Johnson PC, McKinsey DS, Bamberger DM, Sobel JD. Alopecia associated with fluconazole therapy. *Ann Intern Med* 123:354-357, 1995.
157. Duggan JM, Wolf MD, and Kauffman CA: *Phialophora verrucosa* infection in an AIDS patient. *Mycoses* 38:215-218, 1995.
158. Welage LS, Carver PL, Revankar S, Pierson C, and Kauffman CA: Alterations in gastric acidity in HIV-infected patients. *Clin Infect Dis*. 21:1431-1438, 1995.
159. Kauffman CA: Old and new therapies for sporotrichosis. *Clin Infect Dis* 21:981-985, 1995.
160. Tiballi RN, Zarins LT, He X, and Kauffman CA: Susceptibility of *Torulopsis glabrata*: Azole susceptibilities by microdilution colorimetric and macrodilution broth assays. *J Clin Microbiol* 33:2612-2615, 1995.

161. Tiballi, RN, Spiegel JE, Zarins LT, and Kauffman CA. *Saccharomyces cerevisiae* infections and antifungal susceptibility studies by colorimetric and broth macrodilution methods. *Diagn Microbiol Infect Dis* 23:135-140, 1995.
162. Kauffman CA, Pappas PG, McKinsey DS, Greenfield RA, Perfect JR, Cloud GA, Thomas C, Dismukes WE, and the Mycoses Study Group. Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole. *Clin Infect Dis* 22:46-50, 1996.
163. Kauffman CA: The role of azoles in antifungal therapy. *Clin Infect Dis* 22 (Suppl 2):5148-5153, 1996.
164. Duggan JM, Goldstein SJ, Chenoweth, Kauffman CA, and Bradley SF. *Achromobacter xylosoxidans* bacteremia: Report of four cases and review of the literature. *Clin Infect Dis* 23:569-576, 1996.
165. Donta, ST, Peduzzi P, Cross AS, Sadoff J, Haakenson C, Cryz ,SJ, Kauffman, C, Bradley S, et al. for the Federal Hyperimmune Immunoglobulin Trial Study Group. Immunoprophylaxis against *Klebsiella* and *Pseudomonas aeruginosa* infections. *J Infect Dis* 174:537-543, 1996.
166. McKinsey DS, Kauffman CA, Pappas PG, Cloud GA, Girard WM, Sharkey PK, Hamill RJ, Thomas CJ, Dismukes WE, and NIAID Mycoses Study Group. Fluconazole therapy for histoplasmosis. *Clin Infect Dis* 23:996-1001, 1996.
167. Ramsey MA, Bradley SF, Kauffman CA, and Morton TM. Identification of a chromosomal location of the MUP A gene encoding low level mupirocin resistance in staphylococcal isolates. *Antimicrob Agents Chemother* 40:2820-2823, 1996.
168. Bonilla HF, Zarins LT, Bradley SF, Kauffman CA. Susceptibility of ciprofloxacin resistant staphylococci and enterococci to trovafloxacin. *Diagn Microbiol Infect Dis* 26:17-21, 1996.
169. Bonilla HF, Perri, MB, Kauffman CA, Zervos MJ. Comparative in-vitro activity of quinupristin/dalfopristin against multi-drug resistant *Enterococcus faecium*. *Diagn Microbiol Infect Dis* 25:127-131, 1996.
170. Ellison RT, Perez-Perez G, Welsh CH, Blaser MJ, Riester KA, Cross AS, Donta ST, Peduzzi P, and the Federal Hyperimmune Immunoglobulin Therapy Study Group. Risk factors for upper gastrointestinal bleeding in intensive care unit patients: Role of *Helicobacter pylori*. *Crit Care Med* 24:1974-1981, 1996.
171. Bonilla HF, Zervos MJ, Kauffman CA: Long-term survival of vancomycin-resistant *Enterococcus faecium* on a contaminated surface. *Infect Control Hosp Epidemiol* 17:770-771, 1996.
172. Bonilla HF, Chenoweth CE1 Tully, LK, Blythe L, Robertson J, Ognenovski VM, Kauffman CA. *Mycoplasma felis* septic arthritis in a patient with hypogammaglobulinemia. *Clin Infect Dis* 24:222-225, 1997.
173. Hedderwick SA, Bonilla HF, Bradley SF, Kauffman CA. Opportunistic infections in patients with temporal arteritis treated with corticosteroids. *J Am Geriatr Soc* 45:334-337, 1997.
174. Bonilla HF, Zervos MJ, Lyons MJ, Bradley SF, Hedderwick SA, Ramsey MA, Paul LK, Kauffman CA. Colonization with vancomycin resistant *Enterococcus faecium*: Comparison

- of a long-term care unit with an acute care hospital. *Infect Control Hosp Epidemiol* 18:333-339, 1997.
175. Kauffman CA and Carver PL: Antifungal therapy in the 1990s. Current status and further developments. *Drugs* 53:539-549, 1997.
 176. Kauffman CA. Defining the role of systemic azoles in treating fungal infections. *Hospital Formulary* 32:806-819, 1997.
 177. Hedderwick SA, Bonilla HF, Barg NL, Arbeit RD, Kauffman CA. *Mycobacterium avium* complex endocarditis: Spurious diagnosis resulting from laboratory cross-contamination. *Diagn Microbiol Infect Dis* 27:147-150, 1997.
 178. Cheng C-L, Smith DE, Cox SR, Watkins PB, Blake DS, Carver PL, Kauffman CA, Meyer KM, Amidon GL, Stetson PL. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: Effect on erythromycin breath test. *Clin Pharmacol Ther* 61:531-543, 1997.
 179. van der Horst CM, Saag MS, Cloud GA, NIAID Mycoses Study Group and AIDS Clinical Trials Group. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. *N Engl J Med* 337:15-21, 1997.
 180. Pappas PG, Bradsher RW, Kauffman CA, Cloud GC, Thomas CJ, Campbell GD, Chapman SW, Newrnan C, Dismukes WE. Treatment of blastomycosis with higher dose fluconazole. *Clin Infect Dis* 25:200-205, 1997.
 181. Wheat J, MaWhinney S, Hafner R, and the NIAID AIDS Clinical Trials Group and Mycoses Study Group. Treatment of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome. *Am J Med* 103:223-232, 1997.
 182. Edwards JE, Bodey GP, Bowden RA, Buchner T, de Pauw BE, Filler SG, Ghannoun MA, Glauser M, Herbrecht R, Kauffman CA, et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. *Clin Infect Dis* 25:43-59, 1997.
 183. Kauffman CA, Zarins LT. In vitro activity of voriconazole against *Candida* species. *Diagn Microbiol Infect Dis* 31:297-300, 1998.
 184. Hedderwick SA, Wan JY, Bradley SF, Sangeorzan JA, Terpenning MS, Kauffman CA. Risk factors for colonization with yeast species in a long-term care facility. *J Am Geriatr Soc* 46:849-853, 1998.
 185. Ramsey MA, Bradley SF, Morton TM, Reagen DR, Patterson JE, Kauffman CA. Characterization of mupirocin resistant *Staphylococcus aureus* from different geographic areas. *Antimicrob Agents Chemother* 42:1305, 1998.
 186. Kauffman CA, Wiseman SW. Anaphylaxis upon switching lipid-containing amphotericin B formulations. *Clin Infect Dis* 26:1237-1238, 1998.
 187. Bonilla HF, Barg NL, Kauffman CA, Bradley SF. Recurrent necrotizing fasciitis due to group A Streptococcus. *Infect Dis Clin Pract* 7:422-424, 1998.
 188. Ward TT, Rimland D, Kauffman CA, Huycke M, Evans T, Heifets L. Randomized, open-label trial of azithromycin plus ethambutol versus clarithromycin plus ethambutol therapy

- of *Mycobacterium avium* complex bacteremia in patients with human immunodeficiency virus infection. *Clin Infect Dis* 27:1278-1285, 1998.
189. Johnson LB, Bradley SF, Kauffman CA. *Cryptococcus laurentii* fungemia and review of non-*neoformans* cryptococemia. *Mycoses* 41:277-280, 1998.
 190. Nguyen MH, Kauffman CA, Goodman RP, Squier C, Arbeit R, Singh N, Wagener M, Yu VL. *Staphylococcus aureus* nasal carriage and infection in HIV-infected patients. *Ann Intern Med* 130:221-225, 1999.
 191. Kauffman CA, Hedderwick SA, Bradley SF. Antibiotic resistance: Issues in long-term care. *Infections in Medicine* 16:122-128, 1999.
 192. Johnson LB, Burkett JS, Kauffman CA. *Staphylococcus lugdenensis* infection following spinal fusion. *Infect Dis Clin Practice* 8:206-208, 1999.
 193. McKinsey DS, Wheat LJ, Cloud G, Moskovitz B, Pierce M, Slama T, Bamberger D, Goldman M, Thomas CJ, Gutsch H, Moskovitz B, Dismukes WE, Kauffman CA, and the NIAID Mycoses Study Group. Itraconazole prophylaxis against fungal infections in patients with advanced human immunodeficiency virus infection: Randomized placebo-controlled double-blind study. *Clin Infect Dis* 28:1049-1056, 1999.
 194. Bonilla HF, Whitehurst A, Kauffman CA. *Acanthamoeba* sinusitis and disseminated infection in a patient with AIDS. *Infections in Medicine* 16:397-400, 1999
 195. Kauffman CA. Sporotrichosis. State-of-the- Art. *Clin Infect Dis* 29:231-237, 1999
 196. Saag MS, Fessel H, Kauffman CA, Merrill, KW, Ward DJ, Moskovitz EL, Thomas C, Oleka N, Guarnieri JA, Lee J, Brenner-Gati L, Klausner M. Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. *AIDS Research and Human Retroviruses* 15:1413-1417, 1999.
 197. Kauffman CA, Zarins LT. Colorimetric method for susceptibility testing of voriconazole and other triazoles against *Candida* species. *Mycoses* 42:539-542, 1999.
 198. Kauffman CA, Vazquez JA, Sobel JD, Gallis HA, McKinsey DS, Karchmer AW, Sugar AM, Sharkey PK, Wise GJ, Mangi R, Mosher A, Lee JY, Dismukes WE, and the NIAID Mycoses Study Group. A prospective multicenter surveillance study of funguria in hospitalized patients. *Clin Infect Dis* 30:14-18, 2000.
 199. Sobel JD, Kauffman CA, McKinsey D, Zervos M, Vazquez JA, Karchmer AW, Lee J, Dismukes WE, and NIAID Mycoses Study Group. Candiduria: a randomized double blind study of treatment with fluconazole and placebo. *Clin Infect Dis* 30:19-24, 2000.
 200. Kauffman CA, Hajjeh R, Chapman SW. Guidelines for the treatment of sporotrichosis. *Clin Infect Dis* 30:684-687, 2000.
 201. Chapman SW, Eradsher R, Campbell D, Pappas P, Kauffman CA. Guidelines for the treatment of blastomycosis. *Clin Infect Dis* 30:679-683, 2000.
 202. Wheat J, Sarosi G, McKinsey D, Hamill R, Bradsher R, Johnson P, Loyd J, Kauffman C. Guidelines for management of patients with histoplasmosis. *Clin Infect Dis* 30:688-695, 2000.

203. McNeil SA, Clark NM, Chandrasekar PH, Kauffman CA. Successful treatment of vancomycin-resistant *Enterococcus faecium* bacteremia with linezolid after failure of synergic (quinupristin/dalfopristin) treatment. *Clin Infect Dis* 30:403-404, 2000.
204. Goldman M, Cloud GA, Smedema M, Connolly P, McKinsey DS, Kauffman CA, Moskovitz B, Wheat LJ, and the NIAID Mycoses Study Group. Does long-term itraconazole prophylaxis result in azole resistance in mucosal *Candida albicans* isolates from persons with advanced HIV-infection? *Antimicrob Agents Chemother* 44:1585-1587, 2000.
205. Hedderwick SA, McNeil SA, Lyons MJ, Kauffman CA. Pathogenic organisms associated with artificial fingernails worn by health care workers. *Infect Control Hosp Epidemiol* 21:505-509, 2000.
206. Hedderwick SA, Lyons MJ, Liu M, Vazquez, JA, Kauffman CA. Epidemiology of yeast colonization in the intensive care unit. *Eur J Clin Microbiol Infect Dis* 19:663-670, 2000.
207. Schuster TG, Hollenbeck BK, Kauffman CA, Wei JT. Testicular histoplasmosis - a case report. *J. Urology* 164:1652, 2000.
208. Richardson LP, Wiseman SW, Malani PN, Lyons MJ, Kauffman CA. Effectiveness of a vancomycin restriction policy in changing the prescribing patterns of house staff. *Microbial Drug Resistance* 6:327-330, 2000.
209. Malani PN, Bleicher JJ, Kauffman CA, Davenport DS. Disseminated *Dactylaria constricta* infection in a renal transplant recipient. *Transpl Infect Dis* 3:40-43, 2001.
210. McNeil SA, Foster CC, Hedderwick SA, Kauffman CA. The effect of hand cleansing with antimicrobial soap or alcohol-based gel on microbial colonization of artificial fingernails worn by health care workers. *Clin Infect Dis* 32:367-372, 2001.
211. Le Monte AM, Goldman M, Smedema ML, Connolly PA, McKinsey DS, Cloud GA, Kauffman CA, Wheat LJ, & NIAID Mycoses Study Group. DNA fingerprinting of serial *Candida albicans* isolates obtained during itraconazole prophylaxis in patients with AIDS. *Medical Mycology*, 39:207-213, 2001.
212. Hajjeh RA, Pappas PG, Henderson H, Lancaster D, Bamberger DM, Skahan KJ, Phelan MA, Cloud G, Holloway M, Kauffman CA, White LJ, and the MSG Endemic Mycoses Subproject Group. Multicenter, case-control study of risk factors for histoplasmosis in HIV-infected persons. *Clin Infect Dis* 15:1215-1220, 2001.
213. Kauffman CA, Hedderwick SA. Treatment of systemic fungal infections in older patients. Achieving optimal outcomes. *Drugs & Aging* 18:313-323, 2001.
214. Rex JH, Walsh TJ, Nettleson M, Anaissie EJ, Bennett JE, Bow E, Carillo-Munoz AJ, Chavanet P, Cloud GA, Denning DW, dePauw BE, Edwards JE, Hiemenz JW, Kauffman CA, Lopez-Berestein G, Martino P, Sobel JD, Stevens DA, Sylvester R, Tollemar J, Viviani MA, Viscoli C, Wu T. Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. *Clin Infect Dis* 33:95-106, 2001.
215. McNeil SA, Nordstrom-Lerner L, Malani PN, Zervos M, Kauffman CA. An outbreak of *Pseudomonas aeruginosa* sternal surgical site infections traced to a scrub nurse with onychomycosis. *Clin Infect Dis* 33:317-323, 2001.

216. Cinti SK, Armstrong WA, Kauffman CA. Recurrence of increased intracranial pressure with anti-retroviral therapy in an AIDS patient with cryptococcal meningitis. *Mycoses* 44:497-501, 2001.
217. Malani PN, Bradley SF, Little RA, Kauffman CA. Trends in species causing fungemia in a tertiary care medical center over 12 years. *Mycoses* 44:446-449, 2001.
218. Kauffman CA. Fungal infections in older adults. *Clin Infect Dis* 33:550-555, 2001.
219. Pappas PG, Perfect JR, Cloud GA, Larsen RA, Pankey GA, Lancaster DW, Henderson H, Kauffman CA, Haas DW, Saccente M, Hamill R, Holloway MS, Warren RM, Dismukes WE. Cryptococcosis in patients without HIV infection: Management in the era of effective azole therapy. *Clin Infect Dis* 33:690-699, 2001.
220. Wong MT, Kauffman CA, Standiford HC, Fort G, Fuchs HJ, Wenzel RP and the Ramoplanin VRE Study Group. Effective suppression of vancomycin-resistant *Enterococcus* in asymptomatic gastrointestinal carriers by a novel glycolipopeptide, ramoplanin. *Clin Infect Dis* 33:1476-1482, 2001.
221. Perfect JR, Cox GM, Lee JY, Kauffman CA, de Repentigny L, Chapman SW, Morrison VA, Pappas P, Hiemenz JW, and Stevens DA, and the NIAID-sponsored Mycoses Study Group Study. The impact of culture isolation of *Aspergillus*: A hospital-based survey of aspergillosis. *Clin Infect Dis* 33:1824-1833, 2001.
222. Johnson PC, Wheat LJ, Cloud GA, Goldman M, Lancaster D, Bamberger DM, Powderly WG, Hafner R, Kauffman CA, Dismukes WE, and the NIAID Mycoses Study Group. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. *Ann Intern Med* 137:105-109, 2002.
223. Malani P, Thal LA, Donabedian SM, Robinson-Dunn B, Kauffman CA, Chow JW, Hershberger E, Zervos MJ. Molecular analysis of vancomycin resistant *Enterococcus faecalis* from Michigan hospitals during a 10 year period. *J Antimicrob Chemother* 49:841-843, 2002.
224. Day LJ, Qayyum Q, Kauffman CA. Salmonella prosthetic joint septic arthritis. *Clin Microbiol Infect* 8:427-430, 2002.
225. Riddell J, McNeil SA, Johnson TM, Bradley SF, Kazanjian PH, Kauffman CA. Endogenous *Aspergillus* endophthalmitis: Report of three cases and review of the literature. *Medicine* 81:311-320, 2002.
226. Kauffman CA. Management of histoplasmosis. *Expert Opin Pharmacother* 3:1067-1072, 2002.
227. Malani PH, McNeil SA, Bradley SF, Kauffman CA. *Candida albicans* sternal wound infections: A chronic and recurrent complication of median sternotomy. *Clin Infect Dis* 35:1316-1320, 2002.
228. Johnson LB, Kauffman CA. Voriconazole: A new triazole antifungal agent. *Clin Infect Dis* 36:630-637, 2003.

229. Mody L, McNeil SA, Sun R, Bradley SF, Kauffman CA. Effect of introduction of a waterless alcohol-based rub in a long term care facility. *Infect Control Hosp Epidemiol* 24:165-171, 2003.
230. Carver PL, Whang E, VandenBussche HL, Kauffman CA, Malani PN. Arthralgias and/or myalgias related to quinupristin/dalfopristin: risk factors and clinical characteristics. *Pharmacotherapy* 23:159-164, 2003.
231. Bennett JE, Powers J, Walsh T, Viscoli C, dePauw B, Dismukes W, Galgiani J, Glauser M, Herbrecht R, Kauffman C, Lee J, Pappas P, Rex J, Verweij P. Forum Report: Issues in clinical trials of empirical antifungal therapy in febrile neutropenic patients. *Clin Infect Dis* 36(Suppl 3):S117-S122, 2003.
232. Bennett JE, Powers J, dePauw B, Dismukes W, Galgiani J, Glauser M, Herbrecht R, Kauffman C, Lee J, Pappas P, Rex J, Verweij, Viscoli C, Walsh T. Forum Report: Issues in the design of drug trials for invasive aspergillosis. *Clin Infect Dis* 36(Suppl 3):S113-S116, 2003.
233. Bennett J, Kauffman C, Walsh T, dePauw B, Dismukes W, Galgiani J, Glauser M, Herbrecht R, Lee J, Pappas P, Powers J, Rex J, Verweij P, Viscoli C. Forum Report: Issues in the evaluation of diagnostic tests, use of historical controls and the merits of the current multicenter collaborative groups. *Clin Infect Dis* 36(Suppl 3):S123-S127, 2003.
234. Kauffman CA. Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections. *J Antimicrob Chemother* 51:23-30, 2003.
235. Pappas PG, Rex JH, Lee J, Hamill R, Larsen R, Powderly W, Kauffman C, Hyslop N, Mangino J, Chapman S, Horowitz H, Edwards JE, Dismukes WE. A prospective observational study of candidemia: Epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. *Clin Infect Dis* 37:634-643, 2003.
236. Amin K, Kauffman CA. Fever of unknown origin. *Postgraduate Medicine*, 114:69-75, 2003.
237. Kauffman CA. 20 Clinical Pearls: Fungal Infections. *Infect Med* 20:424-436, 2003.
238. Malani PN, Kauffman CA. Diagnosis and management of fungal infections in older adults. *Clin Geriatr* 11:36-44, 2003.
239. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RJ, Horowitz HW, Powderly WG, Hyslop N, Kauffman CA, Cleary J, Mangino JE, Lee J, and the NIAID Mycoses Study Group. Comparative antifungal susceptibility survey of 2000 bloodstream isolates of *Candida* spp. from the United States. *Antimicrob Agents Chemother* 47:3149-3154, 2003.
240. Mody L, Kauffman CA, McNeil SA, Galecki AT, Bradley SF. Mupirocin decolonization of *Staphylococcus aureus* carriers in two long-term care facilities: a randomized, double-blind, placebo-controlled trial. *Clin Infect Dis* 37:1467-1474, 2003.
241. Chapman SW, Pappas P, Kauffman C, Smith EB, Dietze R, Tiraboschi-Foss N, Restrepo A, Bustamante AB, Opper S, Emady-Azar, Bakshi R. Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day⁻¹) in the treatment of cutaneous or lymphocutaneous sporotrichosis. *Mycoses* 47:62-68, 2003.

242. Brandt ME, Kauffman CA, Pappas PG, Iqbal N, Arthington-Skaggs B, Lee-Yang W, Smith MT. Fungemia caused by *Zygoascus hellenicus* in an allogeneic stem cell transplant recipient. *J Clin Microbiol* 42:3363-3365, 2004.
243. DePestel DD, Kazanjian P, Cinti S, Kauffman CA, Carver PL. Magnitude and duration of elevated gastric pH in patients infected with human immunodeficiency virus after administration of chewable, dispersable, buffered didanosine tablets. *Pharmacotherapy* 24:1539-1545. 2004
244. Riddell J, Chenoweth CE, Kauffman CA. Disseminated *Scedosporium apiospermium* infection in a previously healthy woman with HELLP syndrome. *Mycoses*. 47:442-446, 2004.
245. Malani PN, DePestel DD, Riddell J, Bickley S, Klein LR, Kauffman CA. Experience with community-based amphotericin B therapy. *Pharmacotherapy*.

APPEARS THIS WAY
ON ORIGINAL

MANUSCRIPTS SUBMITTED FOR PUBLICATION

1. McNeil SA, Malani PA, Kauffman CA, Fontana RJ, Magee JC, Punch JD, Mackin ML, Chenoweth CE. Vancomycin-resistant enterococcal colonization and infection in liver transplant recipients: Prospective surveillance study.
2. Pappas PG, Andes D, Schuster M, Hadley S, Rabkin J, Merion, RM, Kauffman CA, Huckabee C, Dismukes W. Invasive fungal infections in low risk liver transplant recipients: A multicenter prospective observational study.
3. Ostrosky-Zeichner L, Sable C, Sobel J, Alexander B, Donowitz G, Kan V, Kauffman CA, Kett D, Larsen R, Morrison V, Nucci M, Pappas PG, Bradley ME, Major S, Zimmer L, Wallace D, Rex JH. Multicenter retrospective development and validation of a clinical prediction rule for invasive candidiasis in the intensive care setting.

**APPEARS THIS WAY
ON ORIGINAL**

NON-PEER-REVIEWED PUBLICATIONS

1. Watanakunakorn C, Kauffman CA, and Glotzbecker C: Comparative in vitro activity of seven aminoglycosides against gentamicin and/or tobramycin resistant gram-negative bacilli. *Current Chemotherapy*. Pp 898-900, 1978.
2. Kauffman CA, Silva J, Hayner NS, and Wilcox KR: Lymphocyte function in persons exposed to polybrominated-biphepys-Michigan. *Morbidity Mortality Weekly Report* 27:207-208, 1978.
3. Landrigan PH, Humphrey HEB, Simon D, Wilcox KR, Silva J, Kauffman CA and Heath CW: Cohort study of Michigan residents exposed to polybrominated biphenyls: Epidemiologic and immunologic findings. *Ann NY Acad Sci* 320: 284-294, 1979.
4. Kauffman CA: Acquired Immunodeficiency Syndrome (AIDS). *Washtenaw County Medical Society Bulletin*, October, 1983.
5. Kauffman CA: Acquired Immunodeficiency syndrome: Epidemiologic features, clinical features, pathogenesis, and prevention. In *Proceedings of Symposium on Herpes, Hepatitis, and AIDS*. Rowe, HN (ed.) University of Michigan, Ann Arbor, Michigan, 1984.
6. Kauffman CA and Jones PG: Fever of unknown origin: Diagnostic dilemma in the elderly. *Geriatrics* 39:46-51, 1984.
7. Kauffman, CA: Septic arthritis in the elderly: Differential diagnosis and treatment. *Geriatr Med Today* 5:74-85, 1986.
8. Bradley SF and Kauffman CA: Fever of unknown origin: Pin-pointing the cause. *Drug Therapy* 17:35-52, 1987.
9. Jones PG and Kauffman CA: Candidiasis: Localized and systemic infection. *Therapaeia* 28:17-19, 1987.
10. Terpenning MS and Kauffman CA: Infective endocarditis in elderly and young patients. *Cardiology Board Review* 5:158-170, 1988.
11. Terpenning MS, Buggy BP, and Kauffman CA: Infective endocarditis in the elderly. *Geriatric Med Today* 8:25-28, 1989.
12. Kauffman CA and Terpenning MS: Endocarditis: Problems emerge as our population ages. *Contemporary Internal Medicine* October 1989, 25-30.
13. Kauffman CA and Bradley SF: Current approach to the diagnosis and treatment of pulmonary blastomycosis. *Intern Med for the Specialist* 11:49-58, 1990.
14. Kauffman CA: Worsening pneumococcal infection. *Patient Care*. 25:123-124, 1991.
15. Kauffman, CA, Bradley SF: Management of hepatosplenic candidiasis. *Clinical Advances in the Treatment of Fungal Infections*. 2:4-5, 1991.
16. Kauffman CA: Aging and the immune system: *Geriatric Focus on Infectious Diseases*. 1:4-11, 1991.
17. Bradley, SF, Kauffman CA: Blastomycosis: Diagnosis and treatment. *Clinical Advances in the Treatment of Fungal Infections*. 2:6-7, 1991.

18. Kauffman CA, Bradley SF: Histoplasmosis: Diagnosis and treatment. *Clinical Advances in the Treatment of Fungal Infections*. 2:12-16, 1991.
19. Kauffman CA: Itraconazole, fluconazole and amphotericin B in antifungal therapy. *Current Opinions in Infectious Diseases*. 4:764-768, 1991.
20. Kauffman CA: Fungal infections in the elderly. *Emergency Medicine* 25:24-32, 1993.
21. Kauffman CA: Infective endocarditis in the older patient. *Clin Geriatrics* 1:8-12, 1993.
22. Mulligan ME, Murray-Leslie KA, Ribner BS, Standiford HC, John JF, Kauffman CA, Korvick JA, Yu VL: Methicillin-resistant *Staphylococcus aureus*: A VA consensus approach to prevention and management. *VA Practitioner*. July 1994, p. 47-53.
23. Kauffman CA: using oral antifungal agents for severe fungal infections. *Contemporary Internal Medicine* 7:25-39, 1995.
24. Kauffman CA: Antifungal prophylaxis: Effectiveness in the immunocompromised host. *Postgrad Med (Special Report)*:60-64, 1995.
25. Kauffman CA: Antibiotic preventive interventions for older adults. *Clin Geriatrics* 3:11-23, 1995.
26. Kauffman CA: Non-resolving pneumonia: Is endemic mycosis to blame? *J Respir Dis* 16:1008-1024, 1995.
27. Kauffman CA: Oral antifungal agents in office practice. *Clinical updates in fungal infections*. National Foundation for Infectious Diseases. October 1995.
28. Kauffman CA: Opportunistic fungal infections: Cryptococcosis. *J Respir Dis* 16:1074-1079, 1995.
29. Kauffman CA: Opportunistic fungal infections: The filamentous fungi. *J Respir Dis* 17:17-27, 1996.
30. Kauffman CA, Hedderwick S: Opportunistic fungal infections. Filamentous fungi and cryptococcosis. *Geriatrics* 52:40-49, 1997.
31. Hedderwick SA, Kauffman CA. Opportunistic fungal infections: Superficial and systemic candidiasis. *Geriatrics* 52:50-59, 1997.
32. Kauffman CA: Itraconazole oral solution: clinical review and experience. *AIDS Patient Care and STDs* 11 (suppl 1) :518-521, 1997.
33. Kauffman CA: The changing face of infectious diseases (Editor) *Patient Care*. 1997.
34. Cahill EK, Favero MS, Jarvis WR, Kauffman CA, Pugliese G, Weinstein RA. Long-term care, home care, and hemodialysis settings. In: *Issues and Controversies in Prevention and Control of Vancomycin-resistant Enterococcus*. Pugliese G & Weinstein RA (eds). 1998.
35. Kauffman CA. Fungal infections in immunocompromised hosts. Focus on epidemiologic aspects of infection. National Foundation for Infectious Diseases. February 1998.
36. Warnock DW, DuPont B, Kauffman CA, Sirisanthana T. Imported mycoses in Europe. *Med Mycology* 36(Suppl 1):87-94,1998.

37. Kauffman CA, Bonilla HF. Trends in antibiotic resistance with emphasis on vancomycin-resistant enterococci (VRE). *Family Practice Recertification* 20:80-94, 1998.
38. Kauffman CA. Opportunistic fungal infections: An update on cryptococcosis. *J Crit Illness* 14:129-132, 1999.
39. Kauffman CA. When to suspect fungal infection as the cause of non-resolving pneumonia. *J Respir Dis* 20:283-293, 1999.
40. Kauffman CA. Recognizing histoplasmosis as a cause of pneumonia. *J Respir Dis* 20:351-354, 1999.
41. Kauffman CA. Systemic antifungal agents: What is in the pipeline? *Drugs in R&D*, 1999.
42. Dupont B, Crewe Brown HH, Westermann K, Martins MD, Rex JH, Lortholary O, Kauffman CA. Mycoses in AIDS. *Medical Mycology* 38(suppl 1):259-268, 2000.
43. Tiraboschi IN, Bennett JE, Kauffman CA, Rex JH, Girmenia C, Sobel JD, Menichetti F. Deep Candida infections in the neutropenic and non-neutropenic host: an ISHAM symposium. *Medical Mycology* 38(suppl 1):199-204, 2000.
44. Kauffman CA. Histoplasmosis. *Current Treatment Options in Infectious Diseases* 2:487-491, 2000.
45. Kauffman CA. Blastomycosis. *Current Treatment Options in Infectious Diseases* 2:481-485, 2000.
46. Kauffman CA. Sporotrichosis. *Current Treatment Options in Infectious Diseases* 2:493-497, 2000.
47. Kauffman CA. Pulmonary histoplasmosis. *Current Infectious Diseases Reports* 3:279-285, 2001.
48. Malani PN, Kauffman CA. Invasive and allergic fungal sinusitis. *Current Infectious Diseases Reports* 4:225-232, 2002.
49. Kauffman CA. Candiduria: Diagnostic and treatment conundrums. *Current Treatment Options Infect Dis* 4:513-519, 2002.
50. Kauffman CA. Managing fungal pneumonias: a review of the newer therapies. *J Respir Dis* (in press).

APPEARS THIS WAY
ON ORIGINAL

BOOKS, BOOK CHAPTERS

1. Schwarz J, and Kauffman CA: Histoplasmosis. In: Current Diagnosis, Fifth edition, Conn HF and Conn R Jr. (eds.), 1977, pp. 209-212.
2. Kauffman CA: Cryptococcosis. In: Current Pediatric Therapy, Tenth edition, Kagan BM and Gellis SS, (eds.), 1982, pp. 586-587.
3. Kluger MJ and Kauffman CA: Biologic mechanisms of fever. In: Fever of Undetermined Origin, Murray HW (ed.). Futura Publishing Co, New York, 1983, pp. 9-23.
4. Kauffman CA: Fever of undetermined origin in the elderly. In: Fever of Undetermined Origin, Murray HW (ed.). Futura Publishing Co, New York, 1983, pp. 207-219.
5. Fekety FR, Kauffman CA, Shope TC, Schaberg DR, Gilsdorf JR, and Ross SC: Reviews of Clinical Infectious Diseases, 1984. Grune and Stratton Inc, Orlando, FL, 1984.
6. Kauffman CA: Flucytosine. In: Antimicrobial Agents Annual, volume 1, Peterson PK and Verhoef J (eds.). Elsevier Science Publishers, Amsterdam, 1986, pp. 213-217.
7. Kauffman CA: Flucytosine. In: Antimicrobial Agents Annual, volume 2, Peterson PK and Verhoef J (eds.). Elsevier Science Publishers; Amsterdam, 1987, pp. 218-222.
8. Kauffman CA and Fekety FR: Endocarditis. In: Infectious Diseases in the Elderly, Cunha BA (ed). PSG Publishing, Littleton, MA, 1988, pp. 159-172.
9. Kauffman CA: Flucytosine. In: Antimicrobial Agents Annual, volume 3. Peterson PK and Verhoef J (eds). Elsevier Science Publishers, Amsterdam, 1988, pp. 245-250.
10. Kauffman CA and Bradley SF: Host defense mechanisms in intravenous drug addicts. In: Infections in Intravenous Drug addicts. Levine DP (ed). Oxford Publishing Co., 1990.
11. Shah S, Gordon JJ, and Kauffman CA: Fever. In: Principles and Practice of Emergency Medicine, 3rd edition. Schwartz GA, Cay ten CG, Mangelsen MA, Mayer TA, Hanke BK (eds) .Lea and Febiger, Philadelphia, 1992, pp. 389-401.
12. Kauffman CA: Fungal infections. In: Clin Geriatr Med. 8:777-791, 1992.
13. Kauffman CA: Antifungal agents. In: Antimicrobial Therapy in the Elderly Patient. Yoshikawa TT and Norman DC (eds). Marcel Dekker, Inc., New York, 1993, pp. 441-456.
14. Bradley SF and Kauffman CA. Infections of the central nervous system. In: Principles of Geriatric Medicine and Gerontology. Hazzard WR, Bierman EL, Blass JP, Ettinger WE, Halter JB (eds). McGraw-Hill, Inc., New York, 1994, pp. 1071-1077.
15. Kauffman CA: Blastomycosis. In: Conn's Current Therapy. Rakel RE (ed). W.B. Saunders Co, Philadelphia, PA, 1994, pp. 176-178.
16. Kauffman CA and Bradley SF: Staphylococcus. In: Current Therapy in Infectious Disease. Schlossberg D (ed). Mosby Year Book Inc. 1995.
17. Bradley SF and Kauffman CA: Infections associated with vascular catheters. In: Intensive Care Medicine. Rippe JM, Irwin RS, Fink MP, Cerra FB (eds). Little Brown Publishers. 1995, pp. 1141-1152.
18. Kauffman CA: Histoplasmosis. In: Conn's Current Therapy. Rakel RE (ed). W.B. Saunders Co, Philadelphia, PA, 1996, pp.200-201

19. Kauffman CA and Lynch JP: Fungal pneumonia. In: Pulmonary and Respiratory Therapy Secrets. Parsons PE and Heffner JE (eds). Hanley & Belfus, Inc., Philadelphia, PA, 1996, pp. 150-159.
20. Kauffman CA: Antifungal agents. In: Infectious Disease and Antimicrobial Therapy of the Ears, Nose, and Throat. Johnson JT and Yu VL (eds). W.B. Saunders Co., Philadelphia, PA, 1997, pp. 129-135.
21. Kauffman CA and Carver PL: Use of azoles for systemic antifungal therapy. *Advances in Pharmacology* 39:143-189, 1997.
22. Kauffman CA and Bradley SF: Staphylococcus. In: *Current Therapy in Adult Medicine*, 4th Edition. Kassirer JP & Greene HL (eds) Mosby Year Book Inc., 1997, pp.280-282.
23. Kauffman CA and Bradley SF: Epidemiology of community-acquired infection. In: *The Staphylococci in Human Disease*. Crossley KB & Archer GL (eds). Churchill Livingstone, NY, 1997, pp. 287-308.
24. Kauffman CA: Systemic fungal infections. Chapter 11. In: *Atlas of Infectious Diseases*. Mandell GL (ed). Current Medicine, Philadelphia, PA, 1997.
25. Kauffman CA: Amphotericin B. In: *Invasive Fungal Infections*. Sem Resp Crit Care Med. Lynch JP (ed), 18:281-287, 1997.
26. Bradley SF and Kauffman CA: Infections associated with vascular catheters. In: *Intensive Care Medicine*, 4th edition. Irwin RS, Cerra FB, Rippe JM, (eds). Lippincott Williams & Wilkins, 1998.
27. Hedderwick SA, Bradley SF, Kauffman CA. Antibiotic resistance in long-term care. In: *Bailliere's Clinical Infectious Diseases*. Bula C, Kauffman CA (eds). 5:137-150, 1998.
28. Kauffman CA. Sporotrichosis. In: *Antimicrobial Therapy and Vaccines*. Yu VL, Merigan T, Barriere S (eds). Williams & Wilkins, 1999, pp. 1137-1138.
29. Bradley SF, Kauffman CA. Infections associated with intravascular catheters. In: *Manual of Intensive Care Medicine*. Irwin RS, Cerra FB, Rippe JM (eds). Lippincott Williams & Wilkins, 2000.
30. Malani PA and Kauffman CA. Prevention and prophylaxis of invasive fungal sinusitis in the immunocompromised patient. *Fungal rhinosinusitis: A spectrum of diseases*. *Otolaryngologic Clin N. Amer* 33:301-312, 2000.
31. Kauffman CA. Sporotrichosis. In: *Atlas of Infectious Diseases*, Mandell GL (ed). Current Medicine, Philadelphia, PA, pp. 65-77, 2000.
32. Kauffman CA and Bradley SF. Staphylococcus. In: *Current Therapy in Infectious Disease*. 2nd edition. Schlossberg D (ed). Mosby, Inc, pp. 544-547, 2001.
33. Kauffman CA. Fungal infections. In: *Infectious Diseases in Aging: A clinical handbook*. Yoshikawa TT and Norman DC (eds). Humana Press, Totawa, NJ, pp.211-224, 2001.
34. Kauffman CA and Lynch JP: Fungal pneumonia. In: Pulmonary and Respiratory Therapy Secrets. Parsons PE and Heffner JE (eds). Hanley & Belfus, Inc., Philadelphia, PA, 2001.

35. Kauffman CA, Hedderwick SA. *Candida* and other fungi. In: Infection Management for Geriatrics in Long-Term Care Facilities. Yoshikawa TT and Ouslander JG (eds), Marcel Dekker, New York, pp 449-472, 2002.
36. Malani PM, Kauffman CA, Zervos MJ. Enterococcal disease, epidemiology and treatment. In: The Enterococci: Pathogenesis, Molecular Biology, Antimicrobial Resistance, and Infection Control. Gilmore MS (ed), ASM Press, pp 385-408, 2002.
37. Kauffman CA. Mycotic Infections. Scientific American Medicine, chapter XXXVII, 2002.
38. Kauffman CA. Endemic mycoses in patients with hematologic malignancies. Sem Respir Infect 17:106-112, 2002.
39. Bradley SF, Kauffman CA. Infections associated with vascular catheters. In: Intensive Care Medicine, 5th edition. Irwin RS, Cerra FB, Rippe JM (eds), Lippincott, Williams and Wilkins, 2003.
40. Kauffman, CA. Mycotic Infections. In: Infectious Diseases. The Clinician's Guide to Diagnosis, Treatment, and Prevention. Dale DC (ed), WebMD, Inc., New York, NY, 2003.
41. Wheat LJ, Kauffman CA. Histoplasmosis. Infect Dis Clin North Am 17:1-19, 2003.
42. Kauffman CA. Introduction to the Mycoses. Chapter 378. In: Cecil Textbook of Medicine, 22nd edition, Goldman L and Auseillo D (eds), Elsevier Science, Philadelphia, PA, 2003.
43. Kauffman CA. Histoplasmosis. Chapter 379 In: Cecil Textbook of Medicine, 22nd edition. Goldman L and Auseillo D (eds), Elsevier Science, Philadelphia, PA, 2003.
44. Kauffman CA. Blastomycosis. Chapter 381 In: Cecil Textbook of Medicine, 22nd edition. Goldman L and Auseillo D (eds), Elsevier Science, Philadelphia, PA, 2003.
45. Kauffman CA. Sporotrichosis. Chapter 384 In: Cecil Textbook of Medicine, 22nd edition. Goldman L and Auseillo D (eds), Elsevier Science, Philadelphia, PA, 2003.
46. Kauffman CA. Paracoccidioidomycosis. Chapter 382 In: Cecil Textbook of Medicine, 22nd edition. Goldman L and Auseillo D (eds), Elsevier Science, Philadelphia, PA, 2003.
47. Kauffman CA. Cryptococcosis. Chapter 383 In: Cecil Textbook of Medicine, 22nd edition. Goldman L and Auseillo D (eds), Elsevier Science, Philadelphia, PA, 2003.
48. Kauffman CA. Candidiasis. Chapter 385 In: Cecil Textbook of Medicine, 22nd edition. Goldman L and Auseillo D (eds), Elsevier Science, Philadelphia, PA, 2003.
49. Kauffman CA. Histoplasmosis. In: Clinical Mycology. Dismukes WE, Pappas PG, Sobel JD (eds). Oxford University Press, 2003.
50. Kauffman CA. Endemic mycoses after hematopoietic stem cell or solid organ transplantation. In: Transplant Infections, 2nd edition, Bowden RA, Ljungman P, Paya CV (eds). Lippincott, Williams & Wilkins, Philadelphia, PA, pp 524-534, 2003.
51. Riddell J, Kauffman CA. Chronic myelogenous leukemia. In: Infections in Cancer Patients, Greene JN (ed). Marcel Dekker, New York, pp 87-98, 2004.

69. Kauffman CA. Blastomycoses. In: Conn's Current Therapy. Rackel RE (ed). WB Saunders, Co, Philadelphia, PA, pp 256-258, 2004.
70. Kauffman CA. New antifungal agents. *Sem Respir Crit Care Med* 25:233-239, 2004.
71. Kauffman CA. Antifungal agents. In: Antibiotic Therapy for Geriatric Patients Yoshikawa TT, Rajagopalan S, eds. Marcel Dekker, Inc. New York, 2005
72. Kauffman CA. Fungi In: Antibiotic Therapy for Geriatric Patients Yoshikawa TT, Rajagopalan S, eds. Marcel Dekker, Inc. New York, 2005
73. Kauffman CA. Fungal sinusitis. In: Sinusitis. Brook I (ed.) Marcel Dekker, Inc. New York, 2005
74. Bradley SF, Kauffman CA. Infections associated with vascular catheters. *Manual of Intensive Care Medicine*, 4th Edition, Lippincott, Williams, & Wilkins, 2005
75. Kauffman CA. Introduction to the Fungi and the Mycoses. Chapter 46. In: Schaecter's Mechanisms of Microbial Disease. Engleberg NC, DiRita V, Dermody I (eds). Lippincott Williams & Wilkins, 2005.
76. Kauffman CA. Endemic Mycoses. Chapter 47. In: Schaecter's Mechanisms of Microbial Disease. Engleberg NC, DiRita V, Dermody I (eds). Lippincott Williams & Wilkins, 2005.
77. Kauffman CA. Systemic Mycoses Caused by Opportunistic Fungi. Chapter 48. In: Schaecter's Mechanisms of Microbial Disease. Engleberg NC, DiRita V, Dermody I (eds). Lippincott Williams & Wilkins, 2005.
78. Kauffman CA. Subcutaneous, Cutaneous, and Superficial Mycoses. Chapter 49. In: Schaecter's Mechanisms of Microbial Disease. Engleberg NC, DiRita V, Dermody I (eds). Lippincott Williams & Wilkins, 2005.
79. Kauffman CA. Antifungal Drugs. Chapter 56. In: Schaecter's Mechanisms of Microbial Disease. Engleberg NC, DiRita V, Dermody I (eds). Lippincott Williams & Wilkins, 2005.

**APPEARS THIS WAY
ON ORIGINAL**

EDITORIALS, BOOK REVIEWS

1. Kauffman CA. Quandary about treatment of aspergillomas persists (Editorial). *Lancet* 347:1640, 1996.
2. Kauffman CA. Book Review. Aging, Immunity, and Infection. *Internat J Infect Dis*, 2003.
3. Kauffman CA. Zygomycosis: Reemergence of an old pathogen (Editorial). *Clin Infect Dis* 39:588-590, 2004.

**APPEARS THIS WAY
ON ORIGINAL**

ELECTRONIC PUBLICATIONS

1. Kauffman CA. Sporotrichosis: Basic biology & epidemiology. UpToDate.
2. Kauffman CA. Sporotrichosis: Clinical features, diagnosis, and treatment. UpToDate.
3. Kauffman CA. Candida endophthalmitis. Clinical features, diagnosis, and management. UpToDate.
4. Kauffman CA. Candidemia: Diagnosis and management. UpToDate.
5. Kauffman CA. Candidiasis. Clinical manifestations. UpToDate.
6. Kauffman CA, Campbell J. Candidemia: Diagnosis and management in children. UpToDate.
7. Kauffman CA, Campbell J. Candidiasis: Clinical manifestations in children. UpToDate.
8. Kauffman CA. Hepatosplenic candidiasis (Chronic disseminated candidiasis) UpToDate.
9. Kauffman CA. Candida osteomyelitis and arthritis. UpToDate.
10. Kauffman CA. Candida infections of the central nervous system. UpToDate.
11. Kauffman CA. Overview of Candida Infections. UpToDate.
12. Kauffman CA. Candida endocarditis. UpToDate.
13. Oropharyngeal and esophageal candidiasis in patients without AIDS. UpToDate.
14. Wheat LJ, Kauffman CA. Diagnosis and treatment of disseminated histoplasmosis. UpToDate.
15. Wheat LJ, Kauffman CA. Pathogenesis and clinical manifestations of disseminated histoplasmosis. UpToDate.
16. Wheat LJ, Kauffman CA. Diagnosis and treatment of pulmonary histoplasmosis. UpToDate.
17. Wheat LJ, Kauffman CA. Pathogenesis and clinical manifestations of pulmonary histoplasmosis. UpToDate.
18. Cox GM, Kauffman CA, Burkhart JM. Fungal peritonitis in continuous peritoneal dialysis. UpToDate.
19. Cox GM, Kauffman CA. Fungal infections of the bladder and kidneys. UpToDate.

**APPEARS THIS WAY
ON ORIGINAL**

ABSTRACTS

1. Kauffman CA, Tan JS, Linnemann CC Jr, Rotte T, May D, Schiff GM, and Phair JP: Effects of experimentally induced enterovirus infection upon human host defense. *Clin Res* 20:800, 1972.
2. Kauffman CA, Manzler AD, and Phair JP: Cell-mediated immunity in chronic renal failure. *Fed Proc* 33:727, 1974.
3. Kauffman CA, Tan JS, Linnemann CC Jr, Schiff GM, and Phair JP: Cell-mediated immunity during influenza. *J Clin Invest* 53: 39A, 1974.
4. Kauffman CA, Warth PM, and Phair JP: Lymphocyte function in infective endocarditis. Fifteenth Interscience Conference on Antimicrobial Agents and Chemotherapy, 1975. Abst. #196.
5. Kauffman CA, Carleton JA, and Frame PT: A simple method for the measurement of 5-fluorocytosine in the presence of amphotericin B. Fifteenth Interscience Conference on Antimicrobial Agents and Chemotherapy, 1975. Abst. #209.
6. Kauffman CA, Linnemann CC Jr, Schiff GM, and Phair JP: The effect of viral and bacterial pneumonias on cell-mediated immunity in humans. *Clin Res* 23: 496A, 1975.
7. Phair JP, Bjornson A, Kauffman CA, and Hess EV: Humoral factors and leukocyte function in the aged. *Clin Res* 23:522A, 1975.
8. Israel KS, Kauffman CA, Smith J, White AC, and Brooks GF: Disseminated histoplasmosis in patients with compromised immune mechanisms. *Clin Res* 23:532A, 1975.
9. Kauffman CA, Schiff GM, and Phair JP: The effect of influenza A on cell-mediated immunity in ferrets and guinea pigs. Sixteenth Interscience Conference on Antimicrobial Agents and Chemotherapy, 1976. Abst. #175.
10. Baird IM, Kauffman CA, Wantanakunakorn C, and Phair JP: Rapid diagnosis of bacterial meningitis by latex particle agglutination and counterimmunoelectrophoresis. Sixteenth Interscience Conference on Antimicrobial Agents and Chemotherapy, 1976. Abst. #241.
11. Phair JP, Kauffman CA, Jennings R, and Potter CW. Influenza in the guinea pig. Role of cellular immunity in resistance. *Clin Res* 24:578A, 1976.
12. Kauffman CA, Bjornson AB, and Phair JP: Age, host defense, and pharyngeal acquisition of nosocomial flora. *Clin Res* 25: 378A, 1977.
13. Watanakunakorn C, Kauffman Ca, and Glotzbecker C: Comparative in vitro activity of seven aminoglycosides against gentamicin and/or tobramycin resistant gram-negative bacilli. Tenth International Congress of Chemotherapy, 1977.
14. Kauffman CA and Williams SG: The survival of *Streptococcus pneumoniae* in sputum. Seventeenth Interscience Conference on Antimicrobial Agents and Chemotherapy, 1977. Abst. #371.

15. Roselle GA and Kauffman CA: Amphotericin B and 5-fluorocytosine: Effect on lymphocytes. Seventeenth Interscience Conference on Antimicrobial Agents and Chemotherapy, 1977. Abst. #93.
16. Watanakunakorn C and Kauffman CA: Nosocomial infection with gentamicin resistant gram-negative bacilli. Seventeenth Interscience Conference on Antimicrobial Agents and Chemotherapy, 1977. Abst. #426.
17. Williams ME and Kauffman CA: Transfer factor-like activity in the mouse. Clin Res 25:638A, 1977.
18. Kauffman CA, Israel KS, Schwarz J, and Brooks GF: Histoplasmosis in immunosuppressed patients. First International Histoplasmosis Conference, Atlanta, 1978.
19. Roselle GA and Kauffman CA: Amphotericin B and 5-fluorocytosine: Effect on cell-mediated immunity. Eighteenth Inter-science Conference on Antimicrobial Agents and Chemotherapy, 1978. Abst. #338.
20. Williams ME and Kauffman CA: Murine model of transfer factor. Fed Proc 38:1093, 1979.
21. Severance PJ and Kauffman CA: Comparison of methods for the detection of *Cryptococcus neoformans*. Clin Res 27:651A, 1979.
22. Severance PJ, Kauffman CA, and Sheagren IN: Rapid screening test for *Staphylococcus aureus* using lysostaphin. Clin Res 27: 698A, 1979.
23. Cohen I, Aldridge S, Berardi R, and Kauffman CA: Amphotericin B therapy of cryptococcal pneumonia in an immunosuppressed patient. Amer Soc Hospital Pharmacists Midyear Clinical Meeting, 1979.
24. Kauffman CA, Bergman AG, and Severance PJ: Cell-mediated immunity in the ferret. American Zoologist 19:859, 1979.
25. Kauffman CA: Distemper infection in ferrets: A model of viral-induced anergy. Clin Res 29:388A, 1981.
26. Liepman MK, Kauffman CA, Bergman AG, and Mioduszewski J: Prophylactic trimethoprim/sulfamethoxazole in neutropenic patients. Clin Res 29:729A, 1981.
27. Kauffman CA, Liepman MK, Bergman AG, and Mioduszewski J: Effect of prophylactic trimethoprim/sulfamethoxazole on microbial flora of neutropenic patients. Clin Res 29:729A, 1981.
28. Deery HG, Jones PG, Fekety R, Kauffman CA, Silva J, and Supena R: Moxalactam and *C. difficile* associated diarrhea. Twenty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, 1981. Abst. #326.
29. Liepman MK, Kauffman CA, Bergman AG, and Mioduszewski J: Trimethoprim/sulfamethoxazole prophylaxis in adult patients with acute leukemia. Blood 58: 145A, 1981.
30. Kauffman CA, Liepman MK, Bergman AG, and Mioduszewski J: Prophylactic trimethoprim/sulfamethoxazole: Effect on bacterial and fungal flora. Clin Res 30:371A, 1982.

31. Jones PG, Kauffman CA, and Kluger MJ: Fever in elderly persons: Production of endogenous pyrogen. *Fed Proc* 42:752, 1983.
32. Jones PG, Kauffman CA, and Kluger MJ: Endogenous pyrogen production by monocytes from elderly person. *Clin Res* 31: 366A, 1983.
33. Kauffman CA, Jones PG, and Kluger MJ: Aging and nutrition: Role in decreasing the febrile response to infection. Conference on Nutritional Intervention in the Aging Process, St. Louis, 1983.
34. Jones PG, Kauffman CA, McAuliffe LS, and Liepman MK: Ketoconazole vs nystatin for prevention of fungal infections in neutropenic patients. Twenty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, 1983. Abst. #982.
35. Kauffman CA, Jones PG, and Kluger MJ: Malnutrition and impaired production of leukocytic pyrogen. Twenty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, 1983. Abst. #771.
36. Kauffman CA, Jones PG, and Kluger MJ: Aging and nutrition: Effects on leukocytic pyrogen production by monocytes. *Clin Res* 31:773A, 1983.
37. Tocco-Bradley R, Kauffman CA, and Kluger MJ: Comparison of endogenous pyrogen mediated metabolic alterations in young adult and aged rats in response to endotoxin. *Fed Proc* 43:910, 1984.
38. Schwartz DB, Olson DE, and Kauffman CA: Influence of aspiration on tracheal colonization following endotracheal intubation. *Am Rev Resp Dis* 129:A182, 1986.
39. Swartz DB, Olson DE, and Kauffman CA: Tracheal colonization during respiratory failure. *Clin Res* 32:253A, 1984.
40. Schwartz, DB, Olson DE, and Kauffman CA: The utility of pharyngeal and tracheal cultures during endotracheal intubation. *Chest* 86:335, 1984.
41. Kauffman CA, Tocco-Bradley R, and Kluger MJ: Effect of age on febrile response to endogenous pyrogen. *Clin Res* 32:793A, 1984.
42. Tocco-Bradley R, Kluger MJ, and Kauffman CA: Effect of aging on response to endotoxin and *Salmonella typhimurium*. Twenty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, 1984. Abst. #574.
43. Kaatz G, Gitlin S, Schaberg D, Wilson K, Kauffman C, Seo S, and Fekety R: Application of bacteriophage – bacteriocin typing system to an outbreak of *Clostridium difficile* colitis. Twenty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, 1984. Abst.#267.
44. Kauffman CA, Tocco-Bradley R and Kluger MJ: The effect of aging on the febrile response. *The Physiologic, Metabolic, and Immunologic Activities of Interleukin-1*, Ann Arbor, MI, 1985.
45. Bradley SF, Kauffman CA, Bergman AG, and Kluger MJ: The effect of protein malnutrition on the febrile response. Twenty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, 1985. Abst. #616.

46. Zervos MJ, Kauffman CA, Therasse P, Bergman A, Mikesell TS, and Schaberg DR: Epidemiology of an outbreak due to gentamicin resistant enterococci. Clin Res. 34:388A, 1986.
47. Bradley SF and Kauffman CA: Febrile response to endotoxin: Effect of age and protein malnutrition. Clin Res. 34:513A, 1986.
48. Bradley SF and Kauffman CA: Response to interleukin-1 administration: Effect of age and protein malnutrition. Fed Proc. 45:529, 1986.
49. Zervos MJ, Kauffman CA, Therasse P, Bergman AG and Schaberg DR: Epidemiology of nosocomial infections caused by gentamicin resistant enterococci. Twenty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, 1986. Abst. #713.
50. Terpenning MS, Buggy BP and Kauffman CA: infective endo-carditis: Age-related findings in 143 patients. Twenty-sixth Interscience Conference on Antimicrobial Agents and chemo-therapy, 1986. Abst. #957.
51. Kauffman CA, Zervos MJ, Terpenning MS and Schaberg DR: Gentamicin resistant enterococci: Reservoir in a nursing home. J Am Geriatric Soc 34:912, 1986.
52. Terpenning MS, Buggy BP and Kauffman CA: Infective endocarditis: Comparative presentation, microbiology, morbidity, and mortality in patients over 60. J Am Geriatric Soc 35:87, 1987.
53. Bradley SF and Kauffman CA: Effect of protein malnutrition on interleukin-1 production. Clin Res. 34:962A, 1986.
54. Terpenning MS, Zervos MJ, Schaberg DR and Kauffman CA: Factors associated with colonization by gentamicin resistant enterococci: A comparison of acute and long term care. Clin Res. 34:963A, 1986.
55. Dismukes W, Bradsher R, Girard W, Saag M, Chapman S, Karam G, Stevens D, Kauffman C, Gregg C, Shadomys and the NIAID Mycoses Study Group: Itraconazole therapy for blastomycosis and histoplasmosis. Twenty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, 1986. Abstr. #798.
56. Patterson JE, Mikesell TS, Kauffman CA, Schaberg DR, and Zervos MJ: Geographic range of high level gentamicin resistance plasmids in *S. faecalis*. American Society for Microbiology Annual Meeting, 1987 #C242.
57. Bradley SF and Kauffman CA: Effects of protein malnutrition on the response to Salmonella infection. Fed Proc. 46:440, 1987.
58. Terpenning MS and Kauffman CA: Enterococcal infection and colonization: Comparison of young and elderly patients. American Geriatrics Society Annual Meeting, 1987.
59. Kauffman CA and Bradley SF: In vitro susceptibility of Candida species to a new antifungal agent, LY 121019. American Society for Microbiology Annual Meeting, 1988 F-83.
60. Terpenning MS and Kauffman CA: Nosocomial enterococcal bacteremia in the elderly. American Geriatrics Society Annual Meeting, 1988.

61. Bradley SF and Kauffman CA: Aging and the response to Salmonella infection. FASEB Journal 2:A1730, 1988.
62. Terpenning MS, Allada R, Kauffman CA: Intermittent urethral catheterization: Prospective study of bacteriuria and urinary tract infection. Clin Res. 36:351A, 1988.
63. Bradley SF, Kunkel SL, and Kauffman CA: Age and senescence: Role of cachectin/tumor necrosis factor. J Leuk Biol 44:287, 1988.
64. Bradley SF, Vibhagool A, and Kauffman CA: Age and protein malnutrition: Effect on interleukin-1 activity. Twenty-eighth Interscience Conference on Antimicrobial Agents and chemo-therapy, 1988. Abst. #1342.
65. Terpenning MS, Bulo AN, Allada R, and Kauffman CA: Bacteriuria with intermittent urethral catheterization. Twenty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, 1988. Abst. #1147.
66. Bulo AN, Bradley SF, and Kauffman CA: The effect of LY 121019 in combination with amphotericin B and flucytosine against Candida species. Twenty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, 1988. Abst. #1522.
67. Saag M, Bradsher R, Chapman S, Kauffman CA, Girard W, Steven D, Bowles-Patton C, Dismukes W, and the NIAID Mycoses Study Group: Itraconazole therapy for blastomycosis, histoplasmosis, and sporotrichosis. Twenty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, 1988. Abst. #574.
68. McMurray L, Barg N, Kernodle D, Stratton C, and Kauffman CA: Characteristics of a widespread strain of methicillin-susceptible *S. aureus* from wound infections failing cephalosporin prophylaxis. Twenty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, 1988. Abst. #986.
69. Vibhagool A, Bradley SF, and Kauffman CA: Protection against Salmonella infection with monokines. FASEB J. 3:A2365, 1989.
70. Bradley SF, Vibhagool A, Terpenning MS, and Kauffman CA: Monokines can protect rats against Salmonella infection. J Leuk Biol 46:341, 1989.
71. Bradley SF, Vibhagool A, Fabrick S, Terpenning MS, and Kauffman CA: Monokines in aged/malnourished patients. Clin Res 37:943A, 1989.
72. Terpenning MS, Cederna JE, Ensberg M, Bradley SF, and Kauffman CA: Topical mupirocin treatment of nasal *Staphylococcus aureus* colonization in nursing home patients. Clin Res 37:944A, 1989.
73. Bradley SF, Vibhagool A, Fabrick S, Terpenning MS, and Kauffman CA: Monokines in aged/malnourished patients. Cytokine 1:135, 1989.
74. Terpenning M, Bradley S, Bromberg J, Kaufman L, McFarland M, Voice R, Schaberg D, and Kauffman C: Antibiotic-resistant bacterial colonization in VA long term care. Clin Res. 38:382A, 1990.
75. Terpenning M, Bradley S, Bromberg J, Kaufman L, Voice R, McFarland M, Schaberg D, and Kauffman C: Colonization of geriatric rehab unit patients with antibiotic resistant bacteria. J Am Geriatrics Soc 38:A39, 1990.

76. Bradley SF, Terpenning M, Sottile W, Schaberg D, Kauffman C: Transmission of methicillin resistant *Staphylococcus aureus* in a nursing home. Thirtieth Interscience Conference on Antimicrobial Agents and Chemotherapy, 1990. Abst. #467.
77. Kauffman C, Bradley S, Ross S, Weber D, Band J, Harrison D: Successful treatment of hepatic candidiasis with fluconazole. Thirtieth Interscience Conference on Antimicrobial Agents and Chemotherapy, 1990. Abst. #577.
78. Sangeorzan J, Zervos M, Terpenning M, Donabedian S, Bradley S, Kauffman C: Epidemiology of *C. albicans* in a nursing home setting. Clin Res 38:823A, 1990.
79. Bradley S, Terpenning M, Kauffman C. Methicillin-resistant *Staphylococcus aureus*: Colonization and infection in a long-term care facility. Am Geriatrics Soc Annual Meeting, 1991.
80. Kauffman CA, He X, Bradley S, Terpenning M. Suppression of methicillin-resistant *S. aureus* colonization in a long-term care facility. Am Geriatric Soc Annual Meeting, 1991.
81. Terpenning MS, Bradley S, McFarland M, Zarins L, Jorgensen K, Kauffman C. Antibiotic-resistant bacterial colonization in VA nursing home patients. Am Geriatrics Soc Annual Meeting, 1991.
82. Sharkey PK, Kauffman CA, Graybill JR, Dismukes WE, and Mycoses Study Group. Itraconazole treatment of sporotrichosis. Eleventh Congress of the International Society for Human and Animal Mycology, 1991. Abst. #PS3.100.
83. Sangeorzan J, Kauffman C. Validity of contour-clamped homogeneous electric field (CHEF) electrophoresis. Eleventh Congress of the International Society for Human and Animal Mycology, 1991. Abst. #PS2.1
84. Kerkering T, Pappas P, Kauffman C, Chapman S, Powderly W, Perfect J, Dismukes W. Difficulties encountered in designing & conducting clinical trials for therapy of candidemia. Eleventh Congress of the International Society for Human and Animal Mycology, 1991. Abst. #PS2.28.
85. Kerkering T, Pappas P, Talbot G, Fisher J, Perfect J, Kauffman C, Dismukes W, Chapman S, Galgiani J, Powderly W, Graybill J. Comparison of high and low dose IV amphotericin B therapy of candidemia. Eleventh Congress of the International Society for Human and Animal Mycology, 1991. Abst. #PS2.29.
86. Kauffman CA, He X, Bradley S, Terpenning M. Suppression of methicillin-resistant *S. aureus* colonization in a long-term care facility. Clin Res. 39:417A, 1991.
87. Terpenning MS, Bradley S, McFarland M, Zarins L, Jorgensen K, Kauffman C. Antibiotic-resistant bacterial colonization in VA nursing home patients. Clin Res. 39:417A, 1991.
88. Schaberg DS, Terpenning MS, Robinson K, Bradley S, Dillon W, Kauffman C. Emergence of resistance to Ciprofloxacin in Enterococci. Thirty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, 1991. Abstr. #982.
89. Kauffman C, Terpenning M, He X, Ramsey M, Zarins L, Bradley S. Use of mupirocin to decrease MRSA colonization in a long-term care facility. Thirty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, 1991. Abstr. #33.

90. Denning DW, Pappas PG, Kauffman CA, Hostetler JS, Lee JY, Stevens DA, and the NIAID Mycoses Study Group. Oral itraconazole therapy of invasive aspergillosis. Thirty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, 1991. Abstr. #1158.
91. Vazquez J, Kauffman C, Sobel J, Perri MB, Zervos MJ. A comparative study of in-vitro susceptibility of *Candida* species. Thirty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, 1991. Abstr. #483.
92. Pappas PG, Bradsher RW, Chapman SW, Kauffman C, Feldman A, Cloud GA, Dismukes WE, and the NIAID Mycoses Study Group. Fluconazole in the treatment of Blastomycosis. Thirty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, 1991. Abstr. #1159.
93. Bradley S, Chen Y, Kauffman C. Effect of age on macrophage cytokine production. Thirty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, 1991. Abstr. #83.
94. Chenoweth C, Terpenning M, Bradley S, Schaberg D, Kauffman C. Colonization and Transmission of highly gentamicin resistant enterococci in a long-term care facility. Thirty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, 1991. Abstr. #399.
95. Bradley S, He X, Terpenning M, Ramsey M, Jorgensen K, Zarins L, Kauffman C. Effect of mupirocin on methicillin-resistant *Staphylococcus aureus* prevalence in a nursing home. Clin Res, 39:745A, 1991.
96. Sangeorzan J, Bradley S, Zarins L, Kauffman C. Epidemiology of oropharyngeal yeast colonization and infection in HIV (+) patients (pt). 7th International Immunocompromised Host Society Meeting, 1992.
97. Sangeorzan J, Zarins L, Bradley S, Kauffman C. Epidemiology of yeast colonization in HIV (+) patients: Use of DNA typing system (CHEF). Thirty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, 1992. Abstr. #1200.
98. Pappas P, Kauffman C, Perfect J, Greenfield R, McKinsey D, Newman C, Feldman A, Dismukes W, NIAID Mycoses Study Group. Fluconazole for the treatment of sporotrichosis. Thirty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, 1992. Abstr. #629.
99. Janssen D, Zarins L, He X, Schaberg D, Bradley S, Terpenning M, Kauffman C. Emergence of transferable mupirocin resistance during treatment of MRSA carriers in a long-term care facility. Thirty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, 1992. Abstr. #364.
100. Carver P, Welage L, Revankar S, Jorgensen K, Pierson C, Welch K, Kauffman C. Alterations in gastric pH and gastric microbial colonization in HIV (+) patients. Thirty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, 1993. Abstr. #1698.
101. Terpenning M, Bradley S, Jorgensen K, Wan J, Kauffman C. Risk factors for antibiotic-resistant bacteria colonization and infection in long-term care. J Am Geriatr Soc 41:SA40,1993.

102. He X, Zarins L, Tiballi R, Revankar S, Kauffman C. Colorimetric determination of antifungal MIC endpoints utilizing alamar blue. Am Soc Microbiol, 93rd annual meeting, 1994. Abstr. #F-113.
103. Tiballi R, He X, Zarins L, Sangeorzan J, Bradley S, Kauffman C. *In vitro* susceptibility of fluconazole-resistant strains of *Candida albicans* to itraconazole. Am Soc Microbiol, 93rd annual meeting, 1994. Abstr. #F-109.
104. Ramsey MA, Zarins LT, Bradley SF, Kauffman CA, Morton TM. Identification of the mupirocin resistance gene on the staphylococcal chromosome: Evidence to support IS-mediated recombination. Am Soc Microbiol, 93rd annual meeting, 1994. Abstr. #H246.
105. Pappas PG, Kauffman CA, McKinsey DS, Bradsher RW, Sharkey PK, Chapman SW, Greenfield R, Newman C, Dismukes WE and NIAID Mycoses Study Group. Fluconazole for the treatment of blastomycosis, histoplasmosis and sporotrichosis. Infectious Diseases Society of America, 1994. Abstr. #83.
106. Kauffman, C, Tiballi R. In vitro susceptibility testing of *Saccharomyces cerevisiae* clinical isolates. Am Soc Microbiol, 95th annual meeting, 1995. Abstr. #F-105.
107. Bradley S, Cinti S, Ramsey M, Zarins L, Kauffman C. Mupirocin resistance (MUP-R) in *Staphylococcus aureus* and coagulase negative staphylococci (CNS). Am Soc Microbiol, 95th annual meeting, 1995. Abstr. #A-29.
108. Tiballi RN, Zarins LT, He X, Kauffman CA. In vitro susceptibility testing of *Torulopsis glabrata* clinical isolates. Infectious Diseases Society of America Annual Meeting, 1995. Clin Infect Dis 21:776, Abstr. #340.
109. Gallis H, Vasquez J, Kauffman C, Karchmer A, McKinsey D, Mosher A, Lee J, et al. A prospective multicenter surveillance study of funguria in hospitalized patients. Infectious Diseases Society of America Annual Meeting, 1995, Clin Infect Dis 21:774, Abstr. #328.
110. Kauffman C, Pappas P, McKinsey D, Greenfield R, Cloud G, Dismukes W, et al. Infectious Diseases Society of America Annual Meeting, 1995, Clin Infect Dis 21:773, Abstr. #318.
111. Nguyen MH, Kauffman CA, Arbeit RD, Squier C, Goodman R, Singh N, Yu VL. *Staphylococcus aureus* nasal carriage and infection in HIV infected patients. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1995. Abstr. #257.
112. Duggan JM, Chen Y, Kauffman CA, Bradley SF. Effect of aging on monokine mRNA in response to various microbial cell wall components. J Invest Med, 1995, 43:459A.
113. Bonilla H, Thal L, Donabedian S, Lyons M, Zarins L, Zervos M, Kauffman C. Epidemiology of vancomycin resistant enterococci colonization in a VA Medical Center. J Invest Med, 1995, 43: 485A.
114. Tiballi RN, Zarins LT, Kauffman CA. Colorimetric antifungal susceptibility testing. J Invest Med, 1995, 43:460A.
115. Lyons M, Hedderwick S, Zarins L, Lawn A, Kauffman C. Yeast colonization patterns in the intensive care unit. ASM Conference on *Candida* and Candidiasis: Biology, Pathogenesis, and Management, 1996. Abstr. #B12.

116. Ramsey M, Morton T, Bradley S, Reagan D, Patterson J, Kauffman C. Characterization of high-level mupirocin resistant MRSA strains from three geographic locations. Am Soc Microbiol, 96th Annual Meeting, 1996. Abstr. #A97.
117. Thal LA, Donabedian S, Bonilla H, Kauffman C, Schwalbe RS, Sahm D, Chow JW, Zervos MO. Molecular analysis of "mid-level" gentamicin resistant enterococci from diverse geographic areas. Am Soc Microbiol, 96th Annual Meeting, 1996. Abstr. #A91.
118. Perri MB, Thal LA, Donabedian S, Chow JW, Bonilla H, Kauffman C, Sahm D, Zervos MJ. In vitro susceptibility studies of "mid-level" resistant enterococci. Am Soc Microbiol, 96th Annual Meeting, 1996. Abstr. #A90.
119. Hedderwick S, Lyons M, Zarins L, Lawn A, Kauffman C. Epidemiology of colonization with *Candida* species in the intensive care unit. 6th Annual Meeting of The Society for Healthcare Epidemiology of America, 1996. Abstr. #M17.
120. Cheng CL, Smith DE., Cox SR, Watkins PB, Blake DS, Carver. PL, Kauffman CA, Meyer K, Amidon GL, Stetson PL. Study-state pharmacokinetics of delavirdine in HIV (+) patients: in vivo effect of delavirdine on erythromycin breath test. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1996. Abstr. #A57.
121. Carver P, Welage L, Kauffman C. The effect of food and gastric pH on the oral bioavailability of itraconazole in HIV (+) patients. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1996. Abstr. #A31.
122. Hedderwick S, Bonilla H, Barg N, Arbeit R, Kauffman C. Laboratory cross contamination with *Mycobacterium avium* complex in a patient with culture negative endocarditis. 34th Annual Meeting, Infectious Diseases Society of America, 1996, p. 141.
123. Bonilla H, Zervos M, Lyons M, Bradley S, Paul L, Kauffman C. Colonization with vancomycin resistant enterococci: A comparison of a long-term care unit with an acute care hospital. 34th Annual Meeting, Infectious Diseases Society of America, 1996. Abstr. #55, p. 45.
124. Duggan J, Hsi E, Foreman K, Aronow H, Kauffman C, Nickoloff B. Human herpes virus-8 (HHV-8) in cardiac lymphoma in an AIDS patient. 34th Annual Meeting, Infectious Diseases Society of America, 1996, p. 130.
125. Pappas PG, Hamill RJ, Kauffman CA, Bradsher RW, McKinsey DS, Cloud GW, Dismukes WE. Treatment of cryptococcal meningitis in non-HIV infected patients - A randomized comparative trial. 34th Annual Meeting, Infectious Diseases Society of America, 1996. Abstr. #73, p. 49.
126. McKinsey D, Wheat J, Cloud G, Gutsch H, Thomas C, Wiesinger B, Moscovitz B, Bamberger D, Slama T, Pierce M, Lancaster L, Lancaster D, Threlkeld M, Dismukes W, Kauffman C. Itraconazole is effective primary prophylaxis against systemic fungal infections in patients with advanced HIV infection. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1996. Abstr. #LB9.
127. Ward T, Rimland D, Huycke M, Kauffman C, VA HIV Consortium Study Group. Randomized, open label trial of azithromycin plus ethambutol versus clarithromycin plus ethambutol therapy of MAC bacteremia in AIDS. 34th Annual Meeting, Infectious Diseases Society of America, 1996. Abstr. #241, p. 80.

128. Kauffman CA. New developments in the diagnosis of endemic mycoses. 13th Congress of the International Society for Human and Animal Mycology, 1997. Abstr. #S133.
129. Kauffman CA & Zarins LT. Susceptibility of *C. albicans* & *C. glabrata* to terbinafine (TERB). 13th Congress of the International Society for Human and Animal Mycology, 1997. Abstr. #P501.
130. Thal L, Donabedian S, Chow JW, Bonilla H, Kauffman CA, Clewell DB, Robinson-Dunn B, Zervos M. Pulse field electrophoretic analysis of chromosomal DNA (PGFE) of vancomycin resistant *Enterococcus faecium* from Southeastern Michigan hospitals over a five year period. 97th Annual Meeting, Am Soc Microbiol 1997.
131. Hedderwick S, Wan J, Bradley S, Terpenning M, Kauffman C. Epidemiology of yeast colonization in a long-term care facility. Am Geriatric Soc Annual Meeting, 1997.
132. Hedderwick S, Lyons M, Liu ML, Zarins LT, Kauffman CA. Epidemiology of yeast colonization in the intensive care unit (ICU). 35th Annual Meeting, Infectious Diseases Society of America, Clin Infect Dis 25:476, 1997.
133. Sobel JD, McKinsey D, Kauffman C, Zervos M, Vazquez JA, Lee J, and the Mycoses Study Group. Asymptomatic candiduria: A randomized double blind study of treatment with fluconazole and placebo. 35th Annual Meeting, Infectious Diseases Society of America, Clin Infect Dis 25:357, 1997.
134. Pappas P, Perfect J, Henderson H, Kauffman C, Saccante M, Haas D, Pankey G, Lancaster D, Holloway M, Cloud G, Dismukes W, and Members of the Fungal Trials Study Group. Cryptococcosis in non-HIV infected patients: A multicenter survey. 35th Annual Meeting, Infectious Diseases Society of America, Clin Infect Dis 25:379, 1997.
135. Pappas P, Rex JH, Hamill RJ, Larsen RA, Powderly WG, Horowitz H, Kauffman CA, Chapman SW, Lee J, and the NIAID-MSG Candidiasis Subproject. Current trends in nosocomial candidemia: Results of a large multicenter study. Infectious Diseases Society of America 35th Annual Meeting, Clin Infect Dis 25:357, 1997.
136. Hedderwick S, Lyons M, Ramsay M, Zarins L, Bradley S, Kauffman C. Density & composition of microflora associated with artificial fingernails. 35th Annual Meeting, Infectious Diseases Society of America, Clin Infect Dis 25:476, 1997.
137. Goldman M, Cloud GA, Smedema ML, McKinsey DS, Kauffman CA, Moscovitz B, Wheat J, and the NIAID Mycoses Study Group. Does long-term itraconazole prophylaxis result in azole resistance in mucosal *Candida albicans* isolates from person with advanced HIV-infection? 35th Annual Meeting, Infectious Diseases Society of America, Clin Infect Dis 25:453, 1997.
138. Hedderwick SA, Lyons M, Liu ML, Zarins LT, Kauffman CA. Epidemiology of yeast colonization in the intensive care unit. Clin Res, 1997. Abstr. #87.
139. Hedderwick S, McNeil S, Lyons M, Ramsey M, Kauffman C. Pathogenic organisms associated with artificial fingernail use by health care workers. 8th Annual Meeting, Society for Healthcare Epidemiology of America, 1998.
140. Bradley S, Liu M, Kauffman C. Fewer peritoneal macrophages are capable of expressing TNF mRNA with increasing age. American Geriatrics Society Annual Meeting, 1998.

141. Kauffman CA, Zarins LT. In vitro azole susceptibility testing: NCCLS macrodilution vs. Alamar colorimetric assay. 8th International Congress on Infectious Diseases, 1998.
142. Bradley S, Liu M, Kauffman C. Aging decreases murine peritoneal macrophage TNF mRNA. 10th International Symposium on Infections in the Immunocompromised Host, 1998.
143. Nguyen MH, Yu V, Morris A, Kauffman C. Predictive value of fluconazole MICs determined by E-test method on clinical outcome of patients with candidiasis: Results of prospective studies of patients with candidemia and of patients with oropharyngeal candidiasis. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1998.
144. Nguyen MH, Kauffman CA, Goodman RP, Squier C, Arbeit RD, Singh N, Wagener M, Yu V. *Staphylococcus aureus* colonization and infection in AIDS patients. 10th International Symposium on Infections in the Immunocompromised Host, 1998.
145. Johnson LB, Welage LS, Young EW, Kauffman CA. Urine fluconazole (FLU) concentrations in patients with severe renal insufficiency. 36th Annual Meeting Infectious Diseases Society of America, 1998. Clin Infect Dis 27:987,1998.
146. Richardson LP, Wiseman SW, Lyons MJ, Kauffman CA. The effectiveness of a vancomycin restriction policy in changing the prescribing patterns of residents. 36th Annual Meeting Infectious Diseases Society of America, 1998. Clin Infect Dis 27:964, 1998.
147. Pappas PG, Perfect J, Larsen RA, Pankey GA, Lancaster DW, Henderson H, Kauffman CA, Saccante M, Haas DW, Holloway MS, Cloud GA, Dismukes WE. Cryptococcosis in HIV-negative patients: Analysis of 306 cases. 36th Annual Meeting Infectious Diseases Society of America, 1998. Clin Infect Dis 27:939, 1998.
148. Clancy CJ, Kauffman CA, Morris A, Nguyen ML, Tanner DC, Snyderman DR, Yu VL, Nguyen MH. Correlation of fluconazole MIC and response to therapy for patients with candidemia due to *C. albicans* and non-*C. albicans* spp: Results of a multicenter prospective study of candidemia. 36th Annual Meeting Infectious Diseases Society of America, 1998. Clin Infect Dis 27:938, 1998.
149. Kralovic SM, Roselle GA, Danko LH, Simbartl LA, Kauffman CA. *Candida* Bloodstream infections in the Department of Veterans Affairs. 99th Annual Meeting American Society for Microbiology, Chicago, IL, 1999.
150. Hedderwick S, Lyons M, Liu M, Vazquez J, Kauffman C. Epidemiology of yeast colonization in the intensive care unit. Clinical Microbiology and Infection, 5(suppl 3):281, 1999.
151. McNeil SA, Foster CL, Kauffman CA. Pathogenic organisms associated with artificial fingernails: Is handwashing enough? J Invest Med 47:239A, 1999.
152. Cox GM, Perfect JR, Stevens D, Kauffman CA, Lee J, and NIAID Mycoses Study Group. Hospital-based survey of aspergillosis. 37th Infectious Diseases Society of America Annual Meeting, Philadelphia, PA, November 1999. Clin Infect Dis 29:1008, 1999.

153. Wong MT, Porter SB, Kauffman CA, Standiford HC, Fuchs, HJ, Wenzel RP, and the Ramoplanin Study Group. Clinical efficacy and safety phase II trial of ramoplanin in the colonic decontamination of patients colonized with VRE. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999, Abst #LB-12.
154. McNeil SA, Foster CL, Kauffman CA. The effect of hand cleansing with antimicrobial soap or gel on microbial colonization of artificial nails. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999, Abst #1696.
155. Ward T, Rimland D, Kauffman C, Huycke M, Heifets L, and the VA HIV Consortium Study Group. Low serum levels of clarithromycin correlate with delayed bacteriologic clearance in disseminated *Mycobacterium avium* complex disease. 37th Infectious Diseases Society of America Annual Meeting, Philadelphia, PA, November 1999. Clin Infect Dis 29:1032, 1999.
156. Wong MT, Kauffman CA, Standiford HC, Fuchs HJ, Wenzel RP. Clinical efficacy and safety of a novel glycopeptide, ramoplanin, in the decontamination of the gastrointestinal system of patients colonized with vancomycin-resistant enterococcus. 37th Infectious Diseases Society of America Annual Meeting, Philadelphia, PA, November 1999. Clin Infect Dis 29:968, 1999.
157. Zurenko GE, Todd WM, Hafkin B, Meyers B, Kauffman C, Bock J, Slightom S, Shinabarger D. Development of linezolid-resistant *Enterococcus faecium* in two compassionate use program patients treated with linezolid. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999, Abst #848.
158. Mody, L, McNeil, SA, Kauffman CA, Bradley SF. Mupirocin prophylaxis for *Staphylococcus aureus* colonization in nursing homes. 37th Infectious Diseases Society of America Annual Meeting, Philadelphia, PA, November 1999. Clin Infect Dis 29:986, 1999.
159. McNeil SA, Nordstrom-Lerner L, Kauffman CA. Incidence characteristics, outcomes, & risk factors associated with surgical site infections in veterans undergoing median sternotomy. 37th Infectious Diseases Society of America Annual Meeting, Philadelphia, PA, November 1999. Clin Infect Dis 29:1047, 1999.
160. McNeil SA, Nordstrom-Lerner L, Malani P, Kauffman CA. Outbreak of *Pseudomonas aeruginosa* sternal wound infection traced to a scrub nurse with onycholysis. 4th Decennial International Conference on Nosocomial and Healthcare-associated Infections. Atlanta, March 2000.
161. Malani P, Bradley SF, Little R, Kauffman CA. Trends in species causing candidemia over 12 years. 4th Decennial International Conference on Nosocomial and Healthcare-associated Infections. Atlanta, March 2000.
162. Malani P, Bradley S, Little R, Kauffman C. Candidemia at a tertiary care medical center: Trends in species over 12 years. 11th International Immunocompromised Host Society. Halifax, June 2000.
163. McNeil SA, Malani PN, Nordstrom-Lerner L, & Kauffman CA. Surgical site infections (SSI) among veterans undergoing median sternotomy: A prospective study of risk factors and outcomes. 11th International Immunocompromised Host Society. Halifax, June 2000.

164. Mody L, Kauffman C, Bradley SF. Community acquired pneumonia in older veterans. 11th International Immunocompromised Host Society. Halifax, June 2000.
165. Hamill RJ, Pappas PG, Rex JH, Lee JY, Horowitz H, Kauffman CA, Hyslop N, Larsen RA, Stein DK, Graviss EA, Thomas CJ, the Mycoses Study Group. Multicenter surveillance of non-*albicans* candidemia. 38th Infectious Diseases Society of America Annual Meeting, New Orleans, LA, September 2000. Clin Infect Dis 30:219, 2000.
166. Kralovic SM, Danko LH, Simbartl LA, Kauffman CA, Roselle GA. National surveillance for *Candida* bloodstream infections within Department of Veterans Affairs facilities. 38th Infectious Diseases Society of America Annual Meeting, New Orleans, LA, September 2000. Clin Infect Dis 30:219, 2000.
167. Omer I, Perfect JR, Warren RM, Hamill RJ, Kauffman CA, Pappas PG. Cryptococcosis without central nervous system or pulmonary involvement in HIV-negative patients. 38th Infectious Diseases Society of America Annual Meeting, New Orleans, LA, September 2000. Clin Infect Dis 30:219, 2000.
168. Mody L, McNeil SA, Kauffman CA. Effect of introduction of a waterless alcohol-based hand sanitizer on compliance with hand cleansing and microbial colonization among health care workers in a long term care facility. American Geriatrics Society Annual Meeting, Chicago, IL, May, 2001.
169. McNeil S, Malani F, Nordstrom-Lerner L, Kauffman C. Surgical site infections among veterans undergoing median sternotomy: A prospective study of risk factors and outcomes. 11th Annual Scientific Meeting, Society for Healthcare Epidemiology of America, Toronto, April, 2001. Abstr. #146.
170. McNeil S, Mody L, Sun R, Bradley S, Kauffman C. Introduction of a waterless alcohol-based hand sanitizer in a long term care facility: Does it improve hand cleansing compliance? 11th Annual Scientific Meeting, Society for Healthcare Epidemiology of America, Toronto, April, 2001. Abstr. #10.
171. Carver, PL, Depestel D, Kazanjian P, Kauffman C, Cinti S. Assessing the magnitude and duration of didanosine-induced elevation of gastric pH in HIV+ subjects. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September, 2001. Abstr. #500.
172. Edmond M, McClish D, Massie T, Wiblin RT, Kauffman C, Welage L, Goff D, Rex JH, Schuster M, Wenzel R. Risk factors for nosocomial candidemia among patients in eight surgical intensive care units. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September, 2001. Abstr. #1464.
173. Ostroski-Zeichner L, Rex JH, Pappas PG, Hammill RJ, Larsen RA, Horowitz HG, Powderly WG, Hyslop N, Kauffman CA, Chapman SW, Mangino JE, Lee J. Three year survey of regional and temporal trends in fluconazole resistance among bloodstream *Candida* isolates from the United States. 39th annual Infectious Diseases Society of America Meeting, San Francisco, September, 2001.
174. Rex JH, Ostroski-Zeichner L, Pappas PG, Hammill RJ, Larsen RA, Horowitz HG, Powderly WG, Hyslop N, Kauffman CA, Chapman SW, Mangino JE, Lee J. Antifungal

- susceptibility survey of 2,000 bloodstream *Candida* isolates from the United States. 39th annual Infectious Diseases Society of America Meeting, San Francisco, September, 2001.
175. McNeil SA, Phelps A, Barnes AL, Kauffman CA. The effect of fingernail length on microbial colonization of the hands of health care workers. 39th annual Infectious Diseases Society of America Meeting, San Francisco, September, 2001.
 176. Malani P, Vandenbussche H, Kauffman CA, Whang E, Carver PL. Quinupristin/Dalfopristin: Risk factors for arthralgias and myalgias, American College of Clinical Pharmacy Annual Meeting, 2001.
 177. Mody L, McNeil SA, Galecki A, Kauffman CA, Bradley SF. Mupirocin prophylaxis for staphylococcal infections in long term care facilities. Am Geriatrics Soc Annual Meeting, Washington, D.C., May, 2002, Abstr. #177.
 178. Mody L, McNeil S, Galecki A, Kauffman C, Bradley S. Efficacy of mupirocin in decolonizing persistent staphylococcal carriers among residents of long-term care facilities. Society for Healthcare Epidemiology of America, Salt Lake City, April 2002, Abstr. #223.
 179. Nordstrom-Lerner L, Simmons D, Howard J, Malani P, Kauffman C. Investigation and control of an outbreak of Crusted scabies in a medical unit. Society for Healthcare Epidemiology of America, Salt Lake City, April 2002, Abstr. #269.
 180. Malani P, McNeil S, Bradley S, Kauffman C. *Candida albicans* sternal wound infection: a chronic and recurrent infectious complication of median sternotomy. Society for Healthcare Epidemiology of America, Salt Lake City, April 2002, Abstr. #150.
 181. Malani PN, McNeil SM, Mackin ML, Kauffman CA, Chenoweth CE. Prevalence and outcome of vancomycin resistant enterococci (VRE) colonization in patients awaiting orthotopic liver transplantation. 12th International Immunocompromised Host Society, Bergen, Norway, Internat J Infect Dis, 6(suppl 2):37, 2002.
 182. Riddell J, McNeil SA, Johnson TM, Bradley SF, Kazanjian PH, Kauffman CA. Endogenous *Aspergillus* endophthalmitis: Report of three cases and review of the literature. 12th International Immunocompromised Host Society, Bergen, Norway, Internat J Infect Dis, 6(suppl 2):50, 2002.
 183. Mody L, Kauffman CA, Bradley SF. Efficacy of mupirocin prophylaxis on staphylococcal carriage in nursing home residents. 12th International Immunocompromised Host Society, Bergen, Norway, Internat J Infect Dis, 6(suppl 2):54, 2002.
 184. Malani, P, McNeil S, Bradley S, Kauffman C. *Candida albicans* sternal wound infections among elderly veterans: A chronic and recurrent complication of median sternotomy. 12th International Immunocompromised Host Society, Bergen, Norway, Internat J Infect Dis, 6(suppl 2):55, 2002.
 185. Karchmer AW, Pappas P, Merion R, Cloud G, Hadley S, Rabkin J, Schuster M, Andes D, Kauffman C, Delaney J, Daly J, Kusne S, Alexander B, and Mycoses Study Group. Invasive fungal infection in liver transplant recipients considered at low risk. 40th Annual Meeting, Infectious Diseases Society of America, Chicago, October 2002. Abst. #16.

186. Goldman M, Filler SC, Cloud GA, ACTG 323/MSG40 Study Group. Randomized study of long-term chronic suppressive fluconazole vs. episodic fluconazole for patients with advanced HIV infection and history of oropharyngeal candidiasis. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 2002. Abst. #M1241.
187. Pappas PG, Morgan J, Hajjeh RA, and the Transplant Associated Infection Surveillance Network. Prospective surveillance for invasive fungal infections in hematopoietic stem cell and solid organ transplant recipients in the United States. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 2003. Abst. #M-1010.
188. Miller LG, Man D, Lee C, Lee JY, Dismukes WE, Kauffman C, and NIAID Mycose Study Group. Predictors of candiduria resolution in hospitalized patients: A prospective multi-center investigation. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 2003. Abstr. #M-2059.
189. Hmoud J, Chiu L, Carver P, Bielaczyc A, Kauffman C. *Candida glabrata* fungemia over 8 years in a tertiary care medical center. 41st Annual Infectious Diseases Society of America, San Diego, October 2003, Abst. #348.
190. Hadley S, Daly J, Pappas P, Kauffman C, Rabkin J, Yao J, Schuster M, Karchmer A. A randomized, double-blind trial comparing AmBisome and fluconazole in high-risk liver transplant recipients for prevention of invasive fungal infection. 41st Annual Infectious Diseases Society of America, San Diego, October 2003, Abst #133.
191. Ostrosky-Zeichner L, Sable C, Sobel J, Alexander B, Donowitz G, Kan V, Kauffman CA, Kett D, Larsen R, Morrison V, Nucci M, Pappas PG, Bradley ME, Major S, Wallace D, Rex JH. Multicenter retrospective development and validation of a clinical prediction rule for invasive candidiasis in the intensive care setting. Focus on Fungus, March 2004.
192. Nasia S, Andes, DR, Schuster N, Hadley S, Alexander B, Somani J, Brumble L, Kauffman C, Pappas P, Transnet CDC, Atlanta, GA. Epidemiology and risk factors associated with *Candida non-albicans* infection in organ transplant recipients: Prospective surveillance results from the TRANSNET database. 42nd Annual Infectious Diseases Society of America, Boston, October, 2004, Abst. #682.
193. Nailor MD, Carver PL, Depestel DD, Kauffman CA, University of Michigan, Ann Arbor, Ann Arbor VA Health System, Ann Arbor, MI. Epidemiology of *Scedosporium* species: Colonization or infections? 42nd Annual Infectious Diseases Society of America, Boston, October, 2004, Abst. #609.
194. Miller LG, Zhang H, Cronin J, Lee J, Dismukes WE, Kauffman CA, Harbor-University of California, Los Angeles. Factors associated with funguria treatment in hospitalized patients: insights into physicians' antibiotic prescribing behavior when evidence of infection may be lacking. 42nd Annual Infectious Diseases Society of America, Boston, October, 2004, Abst. #600.